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ABSTRACT 
THE EFFECTS OF COCAINE AND ECSTASY ON CARDIAC MYOCYTES AND 
THE INTACT MYOCARDIUM 
David A. Tiangco 
Old Dominion University, 2010 
Director: Dr. Barbara Y. Hargrave 
Cocaine and ecstasy are widely used illicit drugs. Both drugs have undergone 
intense scrutiny as information regarding their side-effects has become available. One 
important yet incomplete area of investigation pertains to their effects on the heart. The 
purpose of the current studies was to test the hypothesis that exposure to cocaine or 
ecstasy will adversely affect cellular homeostasis and normal heart function. Cultured 
cardiac myocytes (H9c2) and New Zealand White rabbits (Oryctolagus cuniculus) were 
used to measure the responses to various concentrations of cocaine or ecstasy at both the 
cellular and intact organ system levels. We observed that cocaine and ecstasy 
significantly altered several homeostatic parameters including reactive oxygen species 
generation, intracellular calcium balance, NF-KB activity, gene expression, and left 
ventricular function. We conclude that cocaine and ecstasy are detrimental to the 
myocardium of the heart, causing several disturbances with pathological potential. 
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INTRODUCTION 
COCAINE 
Background 
Cocaine (benzoylmethylecgonine) is a naturally occurring alkaloid isolated from 
the leaves of Erythroxylon coca, a South American shrub.1 This drug has a long history 
and high frequency of abuse. A hair analysis study of a random adult population at a 
major university in the United States revealed a 6% use/exposure rate.2 A recent 
government estimate places the use of cocaine among United States teens at 
approximately 4.8%, making it second only to marijuana in illicit drug use.3 Cocaine is 
highly addictive and often taken for its euphoric and stimulatory properties. However, 
this drug also has many unwanted side-effects, including some that adversely affect the 
cardiovascular system. 
Cocaine was the first local anesthetic agent in clinical use, and it was often 
prescribed for ophthalmic and dental procedures.1,4 The anesthetic property of 
cocaine relates to its ability to bind voltage-gated sodium channels and stabilize the 
inactive conformation, thereby blocking trans-membrane conduction and intercellular 
signaling in excitable tissues.5'6 In the heart, this effect may impair conduction velocity 
through the myocardium or impede it altogether, thereby causing an arrhythmia or 
cardiac arrest. In addition, cocaine has several sympathomimetic properties including the 
ability to potentiate the release of epinephrine and norepinephrine from the adrenal 
medulla.7 This may cause excess catecholaminergic stimulation to the heart and blood 
The model for this thesis is Circulation. 
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vessels, leading to increased heart rate, contractility, myocardial wall stress, and 
vasoconstriction. Elevated circulating catecholamines may also lead to activation of the 
renin-angiotensin system which causes an increase in the vasoconstrictor angiotensin II, 
further raising blood pressure and increasing the afterload on the heart. Cocaine also 
blocks the reuptake of norepinephrine and dopamine by binding to specific transport 
proteins at pre-synaptic terminals and inhibiting their function.1'8'9 This effect potentiates 
the actions of epinephrine and norepinephrine at post-synaptic sites such as the 
myocardium and blood vessel walls. Cocaine is currently registered as a schedule II 
compound with the Drug Enforcement Agency (DEA) of the United States in 
recognition of its high abuse potential and limited medical use. 
Toxicodynamics 
Cocaine can be ingested or injected, however it is mostly internalized across oral, 
nasal, or respiratory mucosal membranes via snorting or smoking. Two major forms of 
the drug exist: the hydrochloride salt which is often snorted and the highly concentrated 
free base known as "crack" which often smoked.10 A common recreational dose is 
approximately 175 mg.11 However, the total amount can vary widely since frequent self-
administration within a short time period is typical for an addict with unfettered access 
to the drug.11 
In a study involving healthy human volunteers, a single intranasal dose of 
1.5 mg/kg cocaine gave rise to peak plasma concentrations ranging from 120 to 
474 ng/ml at approximately 15 to 60 min after administration.12 In another study, healthy 
human volunteers were given a 175 mg dose of cocaine at the beginning of every hour 
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over a 4 h time period.11 With this treatment, a dose dependent increase in plasma 
concentration of cocaine was observed with peak levels ranging from 625 to 
738 ng/ml at approximately 4.5 h after the first administration. 
Plasma half-life for cocaine ranges from 45 to 90 min.13 The major route of 
elimination involves breakdown by plasma and liver cholinesterases into the less toxic 
metabolites benzoylecgonine (BE) and ecgonine methyl ester (EME) which are water 
soluble and excreted into the urine. " Despite its reduced toxicity, EME has been 
shown to be detrimental to cardiovascular function during pregnancy.18 Norcocaine (NC) 
is a minor N-demethylation species generated by liver P450 enzymes and constitutes less 
than 5% of the total metabolites.15'19 However, NC may be important in prolonging some 
of the effects of cocaine since it is reabsorbed by enterohepatic circulation and still has 
significant toxicity and pharmacological activity.15'17'20 
Subjective Effects 
The desired effects of cocaine have a variable time course of onset and duration 
depending upon the route of administration. Smoking causes the most rapid onset, taking 
only a few seconds, however the effects last for only a few minutes.10 Snorting and oral 
administration have a more delayed onset, but the effects can last for several minutes to 
a few hours.10 Users frequently report feelings of exhilaration, euphoria, alertness, 
enhanced libido, and increased self-confidence.4'11' ' 
The undesired effects of cocaine are highly variable depending upon the individual 
and may include overwhelming anxiety, irritability, displaced thinking, cardiovascular 
complications, and death.10'11'21 After cessation of use, unpleasant withdrawal symptoms 
usually appear in two stages. Stage one, or acute withdrawal, involves feelings of 
depression, agitation, distress, and paranoia.4'11'21 Stage two, or prolonged withdrawal, 
involves decreased motivation, boredom, anhedonia, and intense cravings for cocaine 
that can be triggered or heightened by environmental cues that remind the user of 
previous use.21 
Addiction is believed to be mediated at least in part by dopamine reuptake 
inhibition in the central nervous system including the nucleus accumbens which is part 
of the mesolimbic system.22'23 This has the effect of potentiating the actions of dopamine 
99 
at postsynaptic neurons. In mice homozygous for a defective dopamine transporter 
gene, excess dopamine accumulates in extracellular spaces and the animals exhibit 
behavioral responses similar to cocaine intoxication.24 It is also believed that serotonin 
reuptake inhibition also contributes to cocaine addiction, but with less priority than 
dopamine signaling.25 
Cardiovascular Toxicity 
Cocaine is the leading cause of drug related deaths and cardiovascular 
9fi 
complications play a major role in this etiology. Asymptomatic heart disease is 
97 
prevalent among chronic cocaine users, affecting an estimated 38%. As a 
sympathomimetic, cocaine is known to cause abnormal increases in heart rate, 
98 "\ 1 
contractility (inotropy), arterial blood pressure, and coronary artery vasoconstriction. 
Decreased coronary flow at a time of increased oxygen demand may cause ischemia in 
the myocardium. In addition, the ability of cocaine to activate blood platelets increases 
the possibility of thrombosis formation and subsequent myocardial infarction or 
stroke.32-35 
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Cocaine can adversely affect the heart indirectly by damaging the kidneys, organs 
with critical functional ties to the cardiovascular system. Renal nephrons are the primary 
structural and functional subunits of the kidney and are responsible for balancing the 
processes of renal filtration, secretion, and reabsorption. By closely regulating these 
three processes, the nephron maintains homeostatic control over blood volume and 
pressure. Chronic cocaine abuse may lead to hypertension induced proteinuria which 
then causes inflammation and dysfunction of proximal tubular epithelial cells of the 
nephron.36'37 Cocaine may also cause rhabdomyolysis, a form of muscle fiber destruction 
with release of sarcoplasmic proteins, and antibody-mediated glomerulonephritis, further 
exposing renal epithelial cells to harmful ultrafiltered proteins.38"43 Rats given daily 
intraperitoneal injections of cocaine (30 mg/kg/day) develop severe tubular epithelial 
necrosis and glomerular sclerosis over the course of several weeks.44 Ultimately, the 
disruption of renal structure and function has deleterious consequences for the heart as it 
works to compensate for the ensuing abnormalities in blood volume and pressure. 
Direct effects of cocaine on the heart have been described. The aforementioned 
anesthetic property of cocaine is related to its ability to inhibit voltage gated sodium 
channel conductance.6 In addition, cocaine can selectively potentiate the activity of the 
L-type calcium channel.45 Cocaine also interferes with energy metabolism by disrupting 
mitochondrial function.46'47 These effects can lead to abnormalities in heart rhythm and 
contractility due to the central role of mitochondrial ATP, sodium, and calcium in the 
excitation-contraction mechanism of the heart. ATP provides energy for myosin cross-
bridge cycling and active transport of Ca2+. Disruption in the supply of ATP may cause 
reduced myocardial contractility (inotropy) and impair the ability of the heart to relax 
6 
(lusitropy). Sodium is responsible for the initial upstroke of depolarization in the 
myocardial action potential. Delayed impulse conduction through the myocardium by 
way of sodium channel inhibition may cause an arrhythmia or lethal ventricular 
fibrillation. Calcium participates in the plateau-phase of the myocardial action potential, 
control of calcium release from the sarcoplasmic reticulum (calcium induce calcium 
release), and removal of tropomyosin inhibition to allow for myosin cross-bridge 
formation upon actin. Potentiation of calcium channel signaling may prolong action 
potential duration which also contributes to arrhythmia formation or ventricular 
fibrillation. Elevated calcium may also cause short-term (due to accompanying lack of 
ATP) elevation in myocardial contractility and decreased lusitropy. Calcium overload 
may also lead to apoptosis via calcinurin mediated dephosphorylation of BAD, release of 
cytochrome C from mitochondrial stores, and subsequent caspase activation.48"50 
Decreasing numbers of functional cardiac myocytes eventually leads to irreparable 
myocardial dysfunction and heart failure. 
One important transcription factor suspected to be involved with the 
cardiovascular toxicity of cocaine is nuclear factor-kappa B (NF-KB). NF-KB is activated 
by oxidizing conditions and helps to regulate the expression of genes associated with 
inflammation, hypertrophy, and fibrosis.51"55 There is presently limited information 
concerning the direct effects of cocaine on NF-KB activity in cardiac myocytes. 
However, cocaine has been shown to activate NF-KB in neurons of the nucleus 
accumbens, endothelial cells of the cerebral vasculature, and tumor derived adrenal 
medullary cells (PC12).56"58 Cocaine also reduces intracellular levels of glutathione, an 
important antioxidant, which may tip the redox balance within the cell in favor of net 
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free-radical generation.59'60 Free-radicals are highly oxidative molecular or atomic 
species that contain an unpaired electron in their orbital structure and have the potential 
to activate NF-KB. 5 1 , 5 2 
Current evidence strongly points towards the possibility of cocaine induced NF-
KB activity in cardiac myocytes. For example, recent studies have described the major 
sources of cocaine induced reactive oxygen species (ROS) generation within cardiac 
myocytes, namely the enzymes NADPH oxidase and xanthine oxidoreductase. ' 
Although ROS are potent activators of NF-KB, these studies did not examine that 
relationship. Moreover, studies in the rat indicate that cocaine can induce myocardial 
inflammation, hypertrophy, and fibrosis, all of which are consistent with NF-KB 
activity.59'63 However, the actual involvement of NF-KB in these studies was not 
measured. 
Our Previous Studies With Cocaine 
Our laboratory has examined the effects of cocaine and its metabolite EME on the 
adult and fetal rabbit cardiovascular system. Evidence indicates that the pregnant female 
and her fetus are more susceptible to the effects of cocaine than the male or non-
pregnant female.18'64'65 Intravenous injection of cocaine (2 mg/kg) increases mean 
arterial pressure (MAP) and blood CO2 concentration (PCO2), but decreases blood pH 
and O2 concentration (PO2) in both males and pregnant females, indicating increased 
sympathetic cardiovascular stimulation with concurrent hypoxemia. Cocaine also 
increases plasma renin activity (PRA) in pregnant females, but not in males an effect that 
may be attributed to the different hormonal environments caused by pregnancy. The 
increase in PRA suggests an increase in angiotensin II, a powerful vasoconstrictor linked 
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to hypertension, myocardial hypertrophy, and heart failure. Intravenous injection of 
EME (2 mg/kg), which is a major metabolite of cocaine in rabbits, increases MAP and 
PRA in pregnant females, but does not affect pCCh or pCh, indicating that this 
metabolite has significant sympathomimetic activity, but lacks the hypoxemic properties 
of the parent compound. 
Experiments have been performed using the Langendorff isolated perfused heart 
method to assess the effects of chronic exposure of the rabbit heart to cocaine, EME, or 
vehicle, and to the stress of global ischemia.18 Our data indicates that hearts exposed to 
cocaine or EME and then stressed with global ischemia demonstrate a significant 
decrease in coronary flow, left ventricular pressure, and heart work index during the 
period of reperfusion than hearts exposed to vehicle (0.9% sodium chloride). These 
studies in vitro and in vivo suggest that cocaine and its metabolite EME alter 
cardiovascular function by increasing left ventricular pressures, and in the presence of 
ishemia-reperfusion, decrease coronary flow to the heart and thus reduce the work 
performance of the left ventricle. However, the mechanisms used by cocaine to reduce 
left ventricular performance are unclear. Therefore, the current studies have been 
performed to help add to our understanding of the mechanisms involved with cocaine 
induced cardiac toxicity and dysfunction. 
ECSTASY 
Background 
3,4-Methylenedioxymethamphetamine (MDMA) is another popular and illicit 
psychoactive drug taken for its mood altering and stimulating effects. MDMA is a 
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favorite party drug among teens and young adults and often goes by the street name 
"ecstasy." A recent government estimate places the lifetime use of MDMA among 
United States teens at approximately 4.1%, making it slightly less used than cocaine, but 
over 3 times more prevalent than heroin.3 Although considered safe and enjoyable by 
many users, current evidence suggests that this drug may also be detrimental to multiple 
internal organs including the heart. 
MDMA shares molecular similarities with its parent compound amphetamine and 
the hallucinogenic substance mescaline.66 An aromatically integrated methylenedioxy 
group is critical to its hybridized structure. The term "designer drug" is often used to 
describe this substance since the synthesis of MDMA deliberately merges the 
physiologic and psychotropic properties of both amphetamine and mescaline into one 
compound. MDMA is currently registered as a schedule I compound with the DEA of 
the United States, denoting its high abuse potential and current lack of legitimate 
medical use. 
Toxicodynam ics 
MDMA is mostly taken orally in tablet form. A common recreational dose can 
range from 50 to 150 mg, although the exact amount of MDMA and the presence of 
contaminants in each tablet can vary greatly depending upon the manufacturer.66 A binge 
pattern of self-administration is characteristic of most users. This typically entails two 
or three consecutive days of drug abuse, usually a weekend, followed by several days of 
abstinence, recovery, and then repetition of the cycle. In addition, MDMA is more likely 
to be taken at social gatherings (ie. parties) as opposed to isolated solitary use. 
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In a study involving healthy human volunteers, single oral administrations of 75 or 
125 mg of MDMA gave rise to peak plasma concentrations of 131 and 236 ng/ml 
respectively.69 Peak levels were observed approximately 2 h after ingestion with an 
elimination half-life on the order of 8 h. Since approximately 6 half-lives are required for 
98% clearance of any drug, it takes about 48 h to obtain this level of clearance for 
MDMA. 
In the liver, cytochrome P450 enzymes known as CYP1A2, CYP2D6, and 
CYP3A4 are the main contributors to MDMA catabolism.70'71 These enzymes lead to 
demethylenation into metabolites such as 3,4-dihydroxymethamphetamine (HHMA) and 
3,4-dihydroxyamphetamine (HHA) followed by urinary elimination as glucuronide or 
sulphate conjugates. Evidence suggests that these enzymes may become saturated or 
non-productively complexed with MDMA as the dose is steadily increased, even within 
the recreational range, causing a non-linear and disproportional elevation in plasma 
concentration relative to actual intake. ' This means that at a certain threshold, which 
may vary from person to person, a small increase in MDMA administration may lead to 
a sudden and large rise in plasma levels, causing acute toxicity in unsuspecting 
individuals. 
Subjective Effects 
The desired effects of MDMA usually appear within one or two hours after 
ingestion, which coincides with rising and peak plasma concentrations.66 Users often 
report an increased sense of alertness, energy, well-being, sociability, and feelings of 
great empathy towards others.66'73'74 The terms "enactogen" or "empathogen" are often 
applied to drugs like MDMA in order to better describe their distinctive psychotropic 
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properties. Reports of enhanced sexual desire are also common in both genders, although 
consummating the act of intercourse may be difficult while under the influence since 
MDMA may cause erectile dysfunction in males.75 
The undesired effects of MDMA are highly variable depending upon the 
individual and may include hyperactivity, confusion, anxiety, bruxism (tooth grinding), 
dry mouth, nausea, vertigo, delirium, psychosis, and death.66'73'74'76 The moderately long 
half-life contributes to the lingering side-effects experienced by some individuals in the 
days following drug use, which may include fatigue, anxiety, depression, and difficulty 
in concentrating.74 Although a certain degree of psychological addiction is readily 
apparent, it is believed that physical addiction to MDMA, in the traditional sense, is 
highly unlikely due to the decrease in desired effects and increase in undesired effects if 
the drug is used too frequently. ' 
Many of the psychological and physical effects of MDMA are related to its ability 
to increase the net concentrations of serotonin and norepinephrine at neuronal terminals 
by subverting the transport mechanisms involved with synaptic reuptake.77'78 With 
abnormal release patterns and impaired synaptic clearance, these neurotransmitters 
improperly and extensively stimulate various post-synaptic targets, including regions of 
the brain and sympathetic end-organs in the periphery.66'79 Elevated serotonin levels 
account for many of the mental components of MDMA intoxication, while the physical 
effects are mainly related to increased norepinephrine signaling.66 Damage to various 
organ systems can occur because of the abnormal neurotransmitter accumulation and by 
the direct and indirect actions of MDMA and its metabolites. 
12 
Cardiovascular Toxicity 
Several adverse cardiovascular effects of MDMA have been observed. In 
otherwise healthy humans, MDMA can cause abnormal increases in heart rate, mean 
80 
arterial pressure, and myocardial wall stress. In rats given regular binge pattern 
intravenous administration of MDMA, increased inflammatory infiltration and lesioning 
of the myocardium can develop within a few weeks.67 This type of administration can 
also cause significant and progressive bradycardia with accompanying hypotension.67 
Autonomic dysregulation is suspected to contribute to the abnormalities in heart rhythm 
and blood pressure seen with MDMA abuse and may involve increased net release of 
norepinephrine from pre-synaptic terminals followed by a- and P-adrenergic receptor 
81 83 
interaction. 
Direct effects of MDMA induced cardiovascular toxicity have also been 
observed. In cultured rat cardiac myocytes, MDMA metabolites alpha-MeDA and N-
Me-alpha-MeDA, both with free radical generating potential, show a higher level of 
84. 
cytotoxicity compared to the parent compound. This finding reveals the importance of 
the peripheral metabolism of MDMA into more toxic forms. In isolated Purkinje fibers, 
MDMA can abnormally prolong action potential duration, a key component of cardiac 
rhythmicity.85 In tumor derived adrenal medullary cells (PC 12), treatment with MDMA 
for 24 h abnormally elevates intracellular Ca2+.86 If cardiac myocytes are affect by 
MDMA in a similar manner, this finding will have important implications for the intact 
4.8 87 88 
heart including myocardial arrhythmia, hypertrophy, fibrosis, and apoptosis. ' ' 
Other lines of evidence illustrate both the direct and indirect cardiotoxic effects of 
MDMA. It is well known that the serotonin release enhancing substance fenfluramine, 
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one of the active ingredients in the banned diet aid Fen-Phen, can induce serotonin 2B 
(5-HT2B) receptor mediated valvular interstitial cell fibroplasia and subsequent heart 
failure.89 MDMA has a similar effect on heart valves by acting as a direct agonist to the 
5-HT2B receptor.90 Furthermore, overexpression of 5-HT2B receptors in the 
myocardium leads to abnormal hypertophy and mitochondrial dysfunction.91 Since 
MDMA also enhances net serotonin release from peripheral stores, the potential for 
5-HT2B receptor agonism and subsequent myocardial hypertrophy, fibrosis, and 
dysfunction is very high with this compound. 
Currently, there is very little information concerning the direct effects of MDMA 
on the heart as it pertains to redox balance, NF-KB activity, or intracellular Ca 
homeostasis. One study showed that MDMA can increase ROS production and deplete 
reduced glutathione levels in hepatic stellate cells. Another study indicates that 
MDMA can increase hydroxyl radical formation in the rat brain. Theoretically, the 
oxidative environments imposed by MDMA administration in these studies represent 
ideal conditions for NF-KB activation and subsequent upregulation of downstream 
genes, including those involved with the inflammatory response. There is already 
evidence that links MDMA administration to increased nitrotyrosine content of proteins 
(an index of ROS activity) within the left ventricle, as well as increased lymphocyte 
infiltration and inflammatory damage to the myocardium (myocarditis).67'94 However, 
the degree of NF-KB involvement with these responses remains unknown. 
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NUCLEAR FACTOR-KAPPA B 
Background 
Nuclear factor-kappa B (NF-KB) is an important and ubiquitous transcription 
factor found most commonly as a heterodimer consisting of p50 and p65 subunits. It was 
first discovered in isolated nuclear fractions as a protein bound to the kappa light chain 
immunoglobulin-enhancer sequence in B cells.95 It has since been found in a wide 
variety of other cell types and shown to be a critical regulator of many biological 
responses including inflammation, growth, and cell survival. 
One important organ affected by NF-KB signaling is the heart. The highly aerobic 
tissues of the heart are particularly susceptible to oxidizing conditions and cytokine 
exposure, important stimulators of NF-KB activity. Recent studies have shown that 
many common pathological conditions of the heart such as ischemia-reperfusion, 
hypertrophic remodeling, and contractile dysfunction are intimately tied to the activation 
status of this transcription factor and the expression of downstream target genes under its 
control. 
NF-KB Structure 
The NF-kB transcription factors are made up of five closely related protein 
subunits: p50, p52, p65, cRel, and RelB. These proteins unite in various combinations 
to form fully functional homodimers and heterodimers, the most common and 
transcriptionally active of which is the p50-p65 complex.97 All NF-KB proteins contain a 
conserved Rel homology region (RHR) which is responsible for subunit dimerization, 
inhibitor binding, sub-cellular localization, and sequence-specific DNA recognition.97'98 
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The overall architecture of each NF-KB protein consists of two immunoglobulin-
no 
like domains joined by a flexible 10-residue segment. Dimer formation occurs by way 
of contacts at the C-terminal dimerization domains on each subunit, giving rise to a 
distinct P-sheet sandwich motif held together by hydrophobic clustering and polar 
interactions.98 The juxtaposition of certain similarly charged residues upon homodimer 
formation makes heterodimer formation energetically more favorable, which helps to 
no 
explain why the p50-p65 complex is so abundant and ubiquitous among cell types. 
The prototypical p50-p65 heterodimer recognizes specific DNA sequences by way 
OS 
of structural loops emanating near the N-terminal and C-terminal domains. In X-ray 
diffraction experiments of co-crystallized NF-KB and DNA, it has been determined that 
the consensus sequence consists of 5'-GGGRNYYYCC-3', where R is a purine, Y is a 
pyrimidine, and N can be any nucleotide.98 It has also been found that the five base-pairs 
in contact with p50 (5'-GGGRN-3') are strictly conserved while the four base-pairs in 
contact with p65 (5'-YYCC-3') tend to be more variable, allowing for some diversity in 
the recognition of promoter sequences from different genes. Significant conformational 
changes in both subunits are observed upon regulatory protein binding and DNA 
97.99 interaction. 
NF-KB Regulation 
Under basal conditions, NF-KB is sequestered in the cytoplasmic compartment by 
binding to the IKB family of inhibitory proteins, the most common and biologically 
active of which is iKBa.97'99 The binding of IicBa to NF-KB causes a drastic 
conformational change in the transcription factor and access to the nuclear localization 
sequences in the RHR becomes sterically blocked.97'99 This effectively inhibits nuclear 
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importation and subsequent activation of downstream dependent genes. In addition, the 
nuclear export sequence on IicBa, which is part of a negative feedback regulatory loop, 
helps to retrieve and remove NF-KB from the nucleus.100 
Activation of NF-KB occurs when IKBO. becomes phosphorylated on a pair of 
critical N-terminal serine residues.101 This action is followed by polyubiquitination 
which targets MBa for the 26S proteasome where it is degraded.101"104 Removal of IKBO. 
uncovers the nuclear localization sequences on NF-KB, which is then free to migrate into 
the nucleus where it can bind to KB-response elements in the promoter and enhancer 
r • 101-103 
regions of various genes. 
NF-KB can be activated by a wide variety of intrinsic and extrinsic stress signals. 
Some of the known stimulators of NF-KB activity include reactive oxygen species 
(ROS), ionizing radiation, tumor necrosis factor alpha (TNFa), interleukin-1 beta 
(IL-1(3), interleukin-6 (IL-6), and bacterial lipopolysaccharides.103'105"107 Some of the 
aforementioned stimulators of NF-KB activity (ie. the cytokines) are actual downstream 
targets of NF-KB mediated transcription.106 It is therefore reasonable to predict that 
under the appropriate conditions, NF-KB activation may lead to a sustained positive 
feedback loop that amplifies the expression of certain inflammatory mediators. 
The detailed mechanisms of NF-KB activation and signal transduction are still 
under intense investigation. However, it is clear that multiple pathways exist depending 
upon the type of stimulus involved. For example, in many cells, DNA-dependent protein 
kinase (DNA-PK) is a serine/threonine kinase that responds to and helps repair double 
stranded DNA breaks.103 Upon inhibition of DNA-PK, TNFa retains while ionizing 
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radiation loses its ability to activate NF-KB. 1 0 3 In cardiac myocytes, toll-like receptor 2 
(TLR2) is involved with the innate immune response to certain bacteria.108 When this 
receptor is blocked by anti-TLR2 antibodies, TNFa retains while hydrogen peroxide 
loses its ability to activate NF-KB. 1 0 8 
Although there is obvious diversity in the upstream signaling pathways that lead to 
NF-KB activation, a convergence exists at the level of IKBO. phosphorylation and 
degradation. IKB kinase (IKK) is a multienzyme complex containing IKKot, IKK|3, and 
IKKy subunits.104 This enzyme phosphorylates the critical N-terminal serine residues on 
IKBOC which are responsible for its eventual degradation and release of NF-KB.1 0 4 IKK is 
believed to be a convergence point immediately upstream of NF-KB activation, serving 
to unify the signaling pathways of many different stimuli known to activate NF-KB. 
However, since its own activity is regulated by phosphorylation, the exact set of protein 
kinases that may be involved in activating IKK and how they themselves are regulated 
remains to be fully characterized. One such IKK-kinase has already been described 
called NF-KB-inducing kinase (NIK), a member of the mitogen-activated protein kinase 
kinase kinase (MAPKKK) family.102'104 Transforming growth factor beta-activated 
kinase 1 (TAK1) is yet another IKK-kinase and its activity has been shown to be 
regulated by protein kinase C beta (PKC|3).109 
Cardiac NF-KB 
Studies have shown that NF-KB activity in the heart is associated with both 
detrimental and beneficial effects. The downstream genes controlled by NF-KB are 
diverse and include inflammatory cytokines, intercellular adhesion molecules, signaling 
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enzymes, and regulatory proteins.106'107'110 The net effect of NF-KB signaling in the heart 
is highly dependent upon the context of activation which in turn determines whether or 
not the response is compensatory or maladaptive. 
In cultured cardiac myocytes, the ROS generating compound hydrogen peroxide 
can activate NF-KB. 5 2 Myocardial intracellular adhesion molecule-1 (ICAM-1) and 
vascular cell adhesion molecule-1 (VCAM-1) are proteins important for leukocyte 
binding and infiltration into the myocardium and are associated with inflammation and 
subsequent myocardial damage.110 ICAM-1 and VCAM-1 gene expression is effectively 
reduced in the presence of NF-KB inhibitors.110'111 Free radical oxidative stress can 
activate NF-KB and lead to increased cytokine and adhesion molecule expression with 
subsequent neutrophil infiltration into the myocardium.112'113 In biopsies of patients with 
end-stage congestive heart failure, NF-KB has been co-localized with the prostanoid 
producing enzyme cyclooxygenase-2 (COX-2) in areas of the myocardium riddled with 
inflammation and fibrotic scar formation. Some evidence suggests that this response 
can be mitigated with antioxidant administration.114 
One of the most frequently encountered heart conditions is the phenomenon of 
ischemia-reperfusion. Ischemia occurs when the blood supply to heart tissue becomes 
greatly impaired or fully blocked, causing a hypoxic condition which, if sufficiently 
sustained, can cause irreversible damage to the myocardium.96 This may happen during a 
heart attack or coronary artery vasospasm. Reperfusion is a period of renewed blood 
flow at significantly increased or near normal levels with a corresponding delivery of 
oxygen back into the myocardium.96 This may occur during anticoagulant treatment after 
a heart attack or immediately after a coronary artery vasospasm subsides. Although 
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reperfusion is ideal and necessary to counter the ultimate effects of ischemia, the sudden 
reintroduction of oxygen to a hypoxic myocardium is known to cause the generation of 
ROS.113 
In sufficient quantities, ROS alone can cause cellular damage, death, and 
myocardial dysfunction.96'113 ROS is also a powerful stimulator of the NF-KB pathway. 
In a study by Chandrasekar et al., the effects of ischemia-reperfusion were observed in 
i n 
the rat heart. In their model, the left anterior descending coronary artery was ligated 
for 45 min and then reperfused for various time points up to 6 h. Compared to control 
animals, the myocardium of ischemia-reperfusion animals had significantly increased 
levels of ROS, NF-KB activity, TNFa, and IL-lp\ In addition, histological examination 
revealed increased neutrophil infiltration concentrated in areas of the myocardium 
directly affected by the ischemia-reperfusion. Neutrophils are the predominate class of 
phagocytic leukocytes during the early stages of inflammation.96 They are responsible 
for causing tissue damage upon their death and subsequent release of cytoplasmic 
contents, including powerful lysosomal enzymes.96 
In another study by Fan et al., the effects of ischemia-reperfusion were observed in 
the dog heart.115 In their model, the left anterior descending coronary artery was 
occluded by an inflated angioplasty balloon for 90 min and then reperfused for either 1 
or 3 h thereafter. Some animals were treated with the ROS scavenger N-(2-
mercaptopropionyl)-glycine (MPG) 5 min prior to reperfusion. It was found that NF-KB 
activity and ICAM-1 expression were significantly elevated in ischemia-reperfusion 
animals that did not receive MPG. This finding illustrates the connections between ROS 
generation, NF-KB activation, and downstream expression of ICAM-1, an important 
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adhesion molecule known to mediate myocardial injury by recruiting neutrophils to the 
area.110'115 
Another frequently encountered condition, especially in the chronically stressed 
and/or failing heart, is myocardial hypertrophy. This condition is characterized by 
enlargement and increased fibrotic remodeling of the myocardium which increases the 
risk for ischemia-reperfusion, ventricular fibrillation, and death due to cardiac 
arrest.96'116 Elevated circulating catecholamines and persistent P-adrenergic receptor 
stimulation are known to be major causes of myocardial hypertrophy and NF-KB activity 
has been shown to be involved with this response.117 Additional evidence in cultured 
ventricular myocytes suggests that NF-KB activity is required for the hypertrophy caused 
by other well known inducing agents such as phenylephrine (an a-adrenergic receptor 
agonist), endothelin-1, and angiotensin II.54 In transgenic mice designed to overexpress 
cardiac myotrophin, suppression of NF-KB activity blocks the development of the 
hypertrophic phenotype normally induced by this gene.118'119 
Abnormal induction of apoptosis is another pathological condition that can affect 
cardiac function. Apoptosis is a normal part of prenatal development, but if it occurs to a 
significant extent in tissues with limited capacities to regenerate (ie. myocardial tissue) 
irreparable functional losses may result.96 NF-KB is believed to exert a pro-survival 
influence in the heart by preventing apoptosis. An important study by de Moissac et al. 
was the first to suggest a link between the anti-apoptotic protein Bcl-2 and NF-KB in 
cultured ventricular myocytes. In their model, Bcl-2 activated NF-KB by enhancing 
proteasomal breakdown of IKBCC. It has also been observed that Bcl-2 loses its anti-
apoptotic properties in cardiac myocytes inhibited for NF-KB activation.121 Moreover, in 
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cultured ventricular myocytes transfected with a non-degradable form of IKB, TNFa 
exposure resulted in significantly increased apoptosis, implying that a functional NF-KB 
pathway is necessary to prevent apoptosis.122 Survival in the face of pro-apoptotic 
signals is essential in the progression of hypertension induced ventricular hypertrophy 
and heart failure where TNFa and circulating catecholamines are chronically 
elevated.54'123'124 
Cardiac NF-KB activity does not always lead exclusively to detrimental effects. In 
some cases, a compensatory component to the overall response is evoked. For example, 
evidence in rats indicates that oxidative stress due to systemic inhalation hypoxia 
activates NF-KB which then upregulates the expression of vascular endothelial growth 
1 9S 1 Oft 
factor (VEGF) in the myocardium. ' VEGF is an important angiogenic factor that 
promotes new blood vessel growth in order to counteract the effects of hypoxia.125'1 6 
Upon subjecting these hypoxic preconditioned rats to myocardial infarction, it was 
observed that the contractile ability of the heart was significantly preserved compared to 
control animals that did not receive hypoxic preconditioning. This finding demonstrates 
a beneficial effect of NF-KB signaling within the same organ under different stimulatory 
context. 
PURPOSE 
The current literature indicates that cocaine and ecstasy are detrimental to 
cardiovascular homeostasis. However, many details of their effects on the heart have yet 
to be fully described. Therefore, our goal in performing these studies was to further 
characterize the effects of these drugs at the cellular and intact organ system level. We 
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predicted that exposure to these drugs would significantly disrupt cellular homeostasis 
and normal heart function. To quantify the effects of these drugs, we used both in vitro 
and in vivo models in separate experimental designs and measure several homeostatic 
parameters including reactive oxygen species generation, intracellular Ca2+ balance, 
NF-KB activity, gene expression, and left ventricular function. We also measured the 
effects of different pre-treatment strategies. The information obtained provides more 
insight into mechanisms by which the heart is affected when these drugs are used. 
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METHODS 
EXPERIMENTS WITH COCAINE 
Dual-Luciferase Luminometry 
In these experiments, we observed the effects of cocaine on NF-KB activity in 
cultured cardiac myocytes. Cocaine is a schedule II substance with the Drug 
Enforcement Agency (DEA) of the United States and was obtained, stored, handled, and 
disposed of in accordance with federal, state, and University regulations by a DEA 
licensed investigator (Dr. Barbara Y. Hargrave). H9c2 cells from the rat (Rattus 
norvegicus) were cultured in sterile 0.2 urn vented T-75 flasks (Corning). These 
embryonic cardiac myoblasts provided an excellent cell model for our studies since they 
are known to have an intact NF-KB signaling system and a drug metabolizing enzyme 
repertoire similar to adult cardiac myocytes. ' Cultures were maintained in an 
aseptically prepared Sheldon model 2310 incubator (Sheldon Manufacturing) at 37°C, 
5% atmospheric CO2, and saturated relative humidity. Culture media consisted of 
Dulbecco's Modified Eagle's Medium™ containing 5% fetal bovine serum (FBS). Cells 
and media were obtained from American Type Culture Collection (ATCC). DNA 
vectors were obtained from Stratagene, Promega, and Dr. Stephen J. Beebe of Eastern 
Virginia Medical School. Manipulations involving viable cells were carried out inside a 
class II biological safety cabinet using sterile equipment and aseptic technique. 
On day 1, after the cells had become approximately 85% confluent, the media in 
the T-75 flask was removed and discarded. Adherent cells were loosened by exposure to 
2 ml of 0.25% trypsin EDTA (ATCC). After 2 min, the trypsin was removed and 
discarded. The cells were then resuspended in 10 ml of fresh media. With the aid of a 
hemacytometer (Fisher), approximately 150,000 cells were plated in duplicates onto 
each well of a sterile 12-well culture plate (Corning). Enough fresh media was added to 
adjust the final volume to 4 ml in each well. The plate was then returned to the incubator 
for 24 h. 
On day 2, the overlying media was removed and discarded. Next, 2 ml of fresh 
media was gently added to each well. The plate was returned to the incubator while the 
transfection solution was being prepared. All cells were transfected using the FuGENE® 
(Roche) method. This technique involves the use of FuGENE® 6, a sterile-filtered lipid-
based transfection reagent that complexes and helps transport DNA into cultured cells. 
FuGENE® 6 has low toxicity and provides high transfection efficiency in many cell 
types including heart cells. The transfection solution for each well was made in separate 
sterile nuclease-free microcentrifuge tubes (Eppendorf). The transfection solution 
consisted of 1.0 p,g firefly luciferase DNA coupled to an inducible NF-KB promoter, 
0.1 ug Renilla luciferase DNA coupled to a constitutively active SV40 promoter, and 
either 1.0 ug pCMV DNA (empty vector) or 1.0 jag IKB DNA coupled to a constitutively 
active CMV promoter. To maintain the concentration of transfected DNA constant 
across all groups, cells that were not given IKB DNA received the empty pCMV DNA 
vector. Enough FBS-free cell culture media (90.7 \x\) and FuGENE® 6 
(6.3 (j.1) was added to achieve a total volume of 100 ul and a 3:1 ratio of FuGENE® 6 to 
total DNA. The transfection solution was allowed to incubate at room temperature for 
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30 min. After incubation, 100 ul of the transfection solution was placed onto the cells by 
direct addition to the 2 ml of media already in each well. The plate was then returned to 
the incubator for 24 h. 
On day 3, the overlying solution was removed and discarded. The cells were then 
stimulated with the following concentrations of cocaine: 0 M, 1X10"4 M, 1X103 M, and 
1X10"ZM. The drug was dissolved in enough cell culture media to achieve each 
concentration and 2 ml of each dose was gently added to the appropriate wells. Cell 
culture media alone (without drug) was added to the cells that served as our 0 M 
controls. To examine the effects of IKB overexpression on cocaine induced NF-KB 
activity, cells co-transfected with IKB DNA were stimulated with either 0 M cocaine or 
the high dose of IX 10"ZM cocaine. Cells serving as controls for this part of the 
experiment (0 M + IKB) were exposed to culture media alone (without drug). All cells 
were stimulated for 24 h. For a summary of the transfection and drug dosage scheme, see 
Tables 1 and 2. 
TABLE 1. Transfection Protocol and Drug Dosage Scheme for H9c2 
Cells Transfected With NF-KB Reporter and Stimulated With Cocaine 
Well# 
1 
2 
3 
4 
5 
6 
7 
8 
Cocaine 
(M) 
0 
0 
1X10-4 
1X10"4 
1X10"3 
IX10"3 
1X10"2 
IX10"2 
NF-KB 
(ug) 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
IKB 
(ug) 
0 
0 
0 
0 
0 
0 
0 
0 
pRL-SV40 
(ug) 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
PC1V 
(ug) 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
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TABLE 2. Transfection Protocol and Drug Dosage Scheme for H9c2 
Cells Co-Transfected With NF-KB Reporter and IKB Overexpression 
Vector and Stimulated With Cocaine 
Well# 
1 
2 
3 
4 
Cocaine 
(M) 
0 
0 
1X10"2 
1X10"2 
NF-KB 
(ng) 
1.0 
1.0 
1.0 
1.0 
IKB 
G*g) 
1.0 
1.0 
1.0 
1.0 
pRL-
G*g) 
0.1 
0.1 
0.1 
0.1 
SV40 PCMV 
fog) 
0 
0 
0 
0 
On day 4, the cells were removed from the incubator and placed on ice. The 
overlying solution was removed and discarded. The cells were washed with 2 changes of 
isotonic phosphate buffered saline (PBS) (pH 7.4) to remove residual drug solution. In 
order to lyse the cells, 250 \A of Passive Lysis Buffer (Promega) was placed into each 
well. This reagent was designed to lyse cells and stabilize both types of luciferase 
enzymes for assay and cold storage. After 15 min, each well was scraped for 30 s with a 
sterile cell scraper (Corning) and the lysate transferred into a new separate 
microcentrifuge tube. Each lysate was vortexed on high for 30 s and then centrifuged at 
14,000X for 3 min. The supernatant (containing luciferase) from each tube was 
transferred into a new separate microcentrifuge tube. 
To sequentially quantify firefly and Renilla luciferase activities, samples were 
analyzed using the Dual-Luciferase™ Reporter Assay System (Promega). All 
proprietary reagents were obtained from Promega unless otherwise indicated. An 
automated dual-injector luminometer connected to a computer was used to control 
reagent delivery, agitate reactants, quantify luminescence, and perform integral 
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calculations. 20 ul aliquots of sample were placed into separate wells of an opaque-
walled 96-well plate (Corning) in duplicates. One-hundred ul of Luciferase Assay 
Reagent was injected and the integral sum of firefly luciferase activity was measured 
over a 5 s read time. Next, 100 ul of Stop & Glo Reagent was injected and the integral 
sum of Renilla luciferase activity was measured over a 5 s read time. The ratio of firefly 
luciferase activity to Renilla luciferase activity was determined and statistical analysis 
(single-factor ANOVA followed by Tukey's test) was performed on all data. Table 3 
summarizes the overall protocol. 
TABLE 3. Summary of the Dual-Luciferase Luminometry Protocol 
Day 1 Day 2 Day 3 Day 4 
Plating Transfection Stimulation Lysis 
(150,000 cells of cells of cells with of cells and 
per well) cocaine or analysis of 
media alone lysate 
In a related set of experiments, we examined the effects of antioxidant pre-
treatment on cocaine induced NF-KB activity. H9c2 cells were cultured and treated as 
previously described with the exception that on day 3 the cells were pre-treated with 
either 1 mM glutathione (Glut), 1 mM N-acetyl-L-cysteine (NAC), or 1 mM Glut + 
1 mM NAC for 15 min. The antioxidants were dissolved in enough cell culture media to 
achieve each concentration and 2 ml of each dose was gently added to the appropriate 
wells. Following pre-treatment, the overlying antioxidant solution was removed and 
discarded. The cells were then exposed to the high dose of 1X10" M cocaine for 6 h. 
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A O M a n d l X K T M cocaine group without any pre-treatment served as controls. 
Reactive Oxygen Species Assay 
In these experiments, we observed the effects of cocaine on ROS generation in 
cultured cardiac myocytes. H9c2 cells were grown and maintained as described in our 
luminometry experiments. The green fluorescent indicator 2',7'-dichlorofluorescin 
diacetate (Molecular Probes) was used to measure the presence of drug induced ROS 
generation. On day 1, with the aid of a hemacytometer, approximately 150,000 H9c2 
cells were plated onto a sterile multi-well culture plate (Corning). The cells were then 
returned to the incubator for 24 h. 
On day 2, the overlying media was removed and discarded. The cells were washed 
with 1 ml of Hank's Media (ATCC) in order to remove residual cell culture media which 
contains a red coloring that might interfere with the indicator. Afterward, each well was 
given 1 ml of new Hank's Media. Indicator solution was made by dissolving enough 
2',7'-dichlorofluorescin diacetate to yield a 5% solution in dimethyl sulfoxide (DMSO) 
(Sigma). To load the cells, 1 ml of the indicator solution was added to each well and the 
culture plate was gently swirled for 1 min. The culture plate was then wrapped in 
aluminum foil and returned to the incubator for 30 min. 
Following the loading period, the cells were washed twice with 1 ml of Hank's 
Media to remove excess indicator not taken up by the cells. Next, 2 ml of fresh Hank's 
Media was placed into each well and the plate was returned to the incubator for 30 min 
prior to drug administration. The following concentrations of cocaine were tested: 
1X10"4 M, 1X10"3 M, and 1X10"2 M. The drug was dissolved in enough Hank's Media to 
achieve each concentration and 2 ml of each dose was gently added to the appropriate 
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wells. Just prior to drug exposure, each well was photographed to obtain a baseline 
signal. This allowed each well to serve as its own 0 M control. The cells were imaged 
using a Zeiss model 510 LSM confocal microscope (Carl Zeiss) equipped with a variable 
wavelength argon laser, epifluorescent filters, and a digital camera. Cells generating 
ROS exhibited a quantifiable green fluorescence. Images were captured 2 and 5 min 
after drug exposure and then analyzed by the program Metamorph (Universal Imaging) 
for densitometry. 
In a related set of experiments, we examined the effects of antioxidant, Ca 
channel blocking, and P-adrenergic receptor blocking pre-treatment on cocaine induced 
ROS generation. H9c2 cells were cultured and treated as previously described with the 
exception that on day 2, the cells were pre-treated with either 1 mM NAC, 10 uM 
verapamil, 10 uM nifedipine, or 10 uM nadolol for 30 min. Following pre-treatment, the 
cells were exposed to the high dose of 1X10" M cocaine. Images were captured 2 and 
5 min after drug exposure with a Zeiss model 510 LSM confocal microscope and then 
analyzed by Metamorph for densitometry. 
Intracellular Calcium Assay 
In these experiments, we observed the effects of cocaine on intracellular Ca2+ 
levels in cultured cardiac myocytes. H9c2 cells were grown and maintained as described 
in our luminometry experiments. On day 1, with the aid of a hemacytometer, 
approximately 150,000 cells were plated onto a sterile multi-well culture plate. The cells 
were then returned to the incubator for 24 h. On day 2, the overlying media was removed 
and discarded. The fluorescent calcium indicator fluo-3 (Sigma) was dissolved in 
enough DMSO to achieve a 1:1000 dilution. The indicator solution was placed onto each 
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well and the plate was returned to the incubator for 30-60 min. The cells were then 
washed twice with 1 ml of Hank's Media to remove excess indicator. The following 
concentrations of cocaine were tested: 1X10"5 M, 1X10"4 M, 1X10"3 M, and 1X10"2 M. 
The drug was dissolved in enough Hank's Media to achieve each concentration and 2 ml 
of each dose was gently added to the appropriate wells. Just prior to drug exposure, each 
well was photographed to obtain a baseline signal. This allowed each well to serve as its 
own 0 M control. Images were captured 2 and 5 min after drug exposure with a Zeiss 
model 510 LSM confocal microscope and then analyzed by Metamorph for 
densitometry. 
In a related set of experiments, we examined the effects of Ca channel blocker 
pre-treatment on cocaine induced intracellular Ca2+ levels. H9c2 cells were cultured and 
treated as previously described with the exception that on day 2, the cells were pre-
treated with either 10 uM verapamil or 10 uM nifedipine for 30 min. Following pre-
treatment, the cells were exposed to either IX10"4 M, IX10"3 M, or 1X10"2 M cocaine. 
Images were captured 2 and 5 min after drug exposure with a Zeiss model 510 LSM 
confocal microscope and then analyzed by Metamorph for densitometry. 
In another related set of experiments, we examined the effects of antioxidant pre-
treatment on cocaine induced intracellular Ca levels. H9c2 cells were cultured and 
treated as previously described with the exception that on day 2, the cells were pre-
treated with 1 raM NAC for 30 min. Following pre-treatment, the cells were exposed to 
either IX10"5 M, 1X10"4 M, 1X10"3 M, or 1X10"2 M cocaine. Images were captured 2 
and 5 min after drug exposure with a Zeiss model 510 LSM confocal microscope and 
then analyzed by Metamorph for densitometry. 
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Gene Array 
In these experiments, we characterized the genetic response of H9c2 cells and 
rabbit myocardium after acute exposure to cocaine. GEArray™ Q Series Kits 
(SuperArray) were used for assessing the transcription levels of certain genes after 
exposure to cocaine. A 96-well array containing genes important to cardiovascular 
pathology was used — Mouse Cardiovascular Disease Biomarkers. A different 96-well 
array containing genes important to cell signaling was also used — Mouse cAMP/Ca + 
Signaling Pathway Finder. A list of all genes and their exact location on each array can 
be found in the appendix or on the SuperArray website (www.superarray.com). 
H9c2 cells were cultured as described in our luminometry experiments. On day 1, 
after becoming approximately 85% confluent, each T-75 flask was treated with either 
0MorlX10"2M cocaine drug solution for 24 h. The drug was dissolved in enough cell 
culture media to achieve each concentration and 10 ml of each dose was gently added to 
the appropriate flask. On day 2, adherent cells were loosened by exposure to 
2 ml of 0.25% trypsin EDTA. After 2 min, the trypsin was removed and discarded. The 
cells were then resuspended in 10 ml of PBS (pH 7.4) and then centrifuged at 2,000X for 
5 min at 4°C. In order to remove residual trypsin, cellular pellets were again resuspended 
in 10 ml of PBS and then centrifuged at 2,000X for 5 min at 4°C. After removal of the 
supernatant, the pellets were processed for RNA extraction. 
To extract total cellular RNA, a Trizol® Reagent (Life Technologies) based 
protocol was used. All steps were performed in a 7°C cold room unless otherwise 
indicated. Tissues harvested from the functional experiments were cut into 1 cm cubes 
and homogenized on ice under 1 ml Trizol® using a Brinkmann Polytron homogenizer 
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(Brinkmann Instruments) while H9c2 pellets were exposed to 0.3 ml Trizol® and mixed 
by inversion. Next, 0.5 ml chloroform (Sigma) was added to each tube for tissue 
specimens while 0.1 ml chloroform was added to each tube for cell pellets. All tubes 
were mixed by brisk shaking for 15 s and then allowed to settle for 2 min. Afterward, all 
tubes were centrifuged at 12,000X for 10 min. The supernatant (containing RNA) was 
carefully removed and placed into separate sterile nuclease-free microcentrifuge tubes. 
To precipitate the RNA, an equal volume of 100% isopropanol (Sigma) was added to 
each tube. After centrifugation at 12,000X for 10 min, the supernatant was removed and 
discarded. The RNA pellet was then resuspended in an equal volume of 70% ethanol 
(Sigma) made in sterile nuclease-free water (HyClone) and centrifuged again at 12,000X 
for 5 min. Afterward, the supernatant was removed and discarded. The RNA pellet was 
air dried at room temperature until most of the visible moisture was evaporated. The 
pellet was then reconstituted with 50 \xl of sterile nuclease-free water followed by brief 
heating in a 55°C water bath to help redissolve the pellet. A 5 ul sample was quality 
checked on a 1% agarose gel containing 10 ul/100 ml GelStar® Nucleic Acid Gel Stain 
(Cambrex) under UV illumination. RNA concentration was determined by 
spectrophotometry (A260 nm). All RNA was stored at -80°C until use. 
A cDNA probe was made from the isolated RNA using a separate annealing and 
labeling procedure. All proprietary reagents were obtained from SuperArray unless 
otherwise indicated. For the annealing mix, 2 ug of RNA from each group was added to 
3 ul of Buffer A in a sterile nuclease-free PCR tube (Fisher). Enough sterile nuclease-
free water was added to fill each tube with 10 ul of total solution. The contents were 
then mixed gently with a pipette and the tubes were incubated in a thermocycler at 70°C 
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for 3 min, followed by 42°C for 2 min. For the labeling mix, 8 JLXI of Buffer BN was 
combined with 4 ul Biotin-16-dUTP (Roche), 2 ul RNAse Inhibitor Solution, 2 ul 
Reverse Transcriptase Solution (50 U/ul), and 4 ul sterile nuclease-free water. The 
contents were stirred gently with a pipette and the tube was incubated at 42°C for 2 min. 
10 ul of labeling mix was added to each annealing mix and the tubes were incubated at 
42°C for 90 min. The labeling reaction was stopped by adding 2 ul of Buffer C. In order 
to block non-specific binding, 3 ml of heat denatured Sheared Salmon Sperm DNA 
Solution (100 ug/ml) was added to the hybridization tubes containing the arrays. The 
tubes were then incubated in a hybridization oven for 2 h at 60°C with continuous 
agitation at 10 RPM (pre-hybridization step). Labeled cDNA probes were denatured by 
heating to 94°C for 5 min and then quickly chilling on ice. After pre-hybridization, the 
denatured probes were added to the appropriate hybridization tubes. The tubes were then 
incubated in a hybridization oven for 48 h at 60°C with continuous agitation at 
10 RPM. 
For chemiluminescent detection, the arrays were washed twice with 5 ml of a 
solution containing 2X saline-sodium citrate (SSC) (Promega) and 1% sodium dodecyl 
sulfate (SDS) (Sigma) — 15 min per wash at 60°C with continuous agitation at 20 RPM. 
The arrays were then washed with a 5 ml of a solution containing 0.5X SSC and 0.5% 
SDS — 15 min per wash at 60°C with continuous agitation at 20 RPM. This slightly less 
stringent secondary wash (normal protocol uses 0.1X SSC and 0.5% SDS) was 
necessary for the optimal hybridization of inter-species cDNA (rat-mouse or rabbit-
mouse). Next, the arrays were exposed to 2 ml Blocking Solution Q for 40 min at room 
temperature with continuous agitation at 20 RPM. The arrays were then incubated with 
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2 ml Alkaline Phosphatase-Conjugated Streptavidin Solution (diluted 1:7,500 in Buffer 
F) for 10 min at room temperature with continuous agitation at 10 RPM. Afterward, the 
arrays were washed 4 times with 4 ml Buffer F — 5 min per wash at room temperature. 
The arrays were then incubated with 1 ml CDP-Star Chemiluminescent Substrate for 
2 min at room temperature. Excess substrate was blotted off gently with clean filter 
paper and the arrays were placed into transparent plastic bags for imaging. 
The arrays were photographed using a dark-chamber digital imaging system 
(BioRad) with computer interface. The image analysis sofware Quantity One (BioRad) 
was used to quantify chemiluminescent signals for each spot on the array. Raw data was 
exported into an Excel (Microsoft) spreadsheet and then analyzed using the GEArray 
Analyzer software downloaded from the SuperArray website (www.superarray.com). As 
per manufacturer's suggestions, all signals were background subtracted from the blank 
on the array and normalized to the constitutively expressed housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Genes with a signal ratio greater 
than 2.0 or less than 0.5 (experimental/control) were considered upregulated or 
downregulated respectively. 
To verify the results, RT-PCR was performed utilizing primer kits obtained from 
SuperArray. Since it was not feasible to perform this procedure for all 96 genes on the 
array, only a few genes from each array were chosen. SingleGene™ PCR kits 
(SuperArray) for the following genes were used: Tnni3, ANG, and KCNA5. First-strand 
cDNA was made from the total RNA isolated in each experiment. To optimize the 
resolution obtained from the different primers, a temperature-gradient PCR was 
conducted with annealing temperatures ranging from 50°C to 65°C. Once the optimal 
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annealing temperature was identified for each specific primer pair, that temperature was 
used for all subsequent PCR analysis involving those primers. One set of primers in each 
primer pair was specific for the array gene being analyzed. The other set of primers was 
specific for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a housekeeping gene 
that is constitutively expressed. The PCR products were subjected to electrophoresis on a 
2% agarose gel containing 10 ul/100 ml GelStar® Nucleic Acid Gel Stain. The gels were 
imaged under a UV illuminator, digitally photographed, and analyzed by the program 
Kodak ID (Eastman Kodak Company) for densitometry. The analysis was semi-
quantitative and ratiometric using the GAPDH signal as an internal normalizer. 
Western Blot 
In these experiments, we measured the protein level expression of array-specific 
genes in H9c2 cells and rabbit myocardium after acute exposure to cocaine. H9c2 cells 
were grown and maintained as described in our luminometry experiments. On day 1, 
after becoming approximately 85% confluent, each T-75 flask was treated with 10 ml of 
either 0 M or 1X10"z M cocaine for 24 hours. The drug was dissolved in enough cell 
culture media to achieve each concentration and 10 ml of each dose was gently added to 
the appropriate flask. 
On day 2, adherent cells were loosened by exposure to 2 ml of 0.25% trypsin 
EDTA. After 2 min, the trypsin was removed and discarded. The cells were then 
resuspended in 10 ml of PBS (pH 7.4) and then centrifuged at 2,000X for 5 min at 4°C. 
In order to remove residual trypsin, cellular pellets were again resuspended in 
10 ml of PBS and centrifuged at 2,000X for 5 min at 4°C. After removal of the overlying 
PBS, the pellets were subjected to the lysis protocol. 
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All pellets were lysed using Radio Immuno Precipitation Assay (RIPA) Lysis 
Buffer (Santa Cruz Biotechnology). This technique involves the use of working RIPA 
Solution which lyses cells and preserves cellular proteins. All proprietary reagents were 
obtained from Santa Cruz Biotechnology unless otherwise indicated. Working RIPA 
Solution was made fresh just prior to use by mixing 1 ml RIPA Lysis Buffer with 10 ul 
Phenylmethylsulfonyl Fluoride (PMSF) Solution, 10 ul Sodium Orthovanadate Solution, 
and 10 ul Protease Inhibitor Cocktail Solution. The working RIPA Solution was added 
to each pellet and the cells were resuspended gently with a disposable pipet. After 
incubation on ice for 30 min, the resuspension was subjected to hydrodynamic shearing 
by forcefully passing the solution through a 21-gauge needle 5 times using a sterile 
syringe. After another incubation on ice for 30 min, the resuspension was transferred to 
separate protease-free microcentrifuge tubes (Eppendorf) and centrifuged at 8,000X for 
10 min in a 7°C cold room. The supernatant (containing cell proteins) was transferred 
into new separate protease-free microcentrifuge tubes and stored at -80°C until use. 
Protein concentration for each sample was determined using the Bradford assay. 
To prepare for Western blotting, samples were diluted in enough sterile protease-
free water (HyClone) to create 65 ul aliquots with an equal total protein concentration of 
1,200 ug/ml. All proprietary reagents, gels, and membranes were obtained from 
Invitrogen unless otherwise indicated. To each 65 ul aliquot, 25 ul of 4X Lithium 
Dodecyl Sulfate (LDS) Sample Buffer and 10 ul of 10X Sample Reducing Agent were 
added to create 100 ul of sample solution. The sample solutions were incubated on a 
heating block at 100°C for 10 min prior to loading onto the gel. Working running buffer 
was made fresh just prior to use by mixing 25 ml of 20X NuPAGE® MOPS Running 
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Buffer with 475 ml double-distilled water (ddl-bO). 25 |al of sample solution was loaded 
onto the appropriate lanes of a NuPAGE® Novex 4-12% bis-tris polyacrylamide gel 
alongside HiMark™ pre-stained protein standard molecular weight markers. 1,250 u,l of 
Antioxidant Solution was added to the working running buffer just prior to the 
electrophoresis. 
The gels were run initially at 200 V and then at 150 V as the tracking dye neared 
the bottom of the gel. After electrophoresis, the gels were prepared for transfer to 
nitrocellulose membrane. Working transfer buffer was made fresh just prior to use by 
mixing 20 ml of 20X NuPAGE® Transfer Buffer with 340 ml ddH20 and 40 ml of 100% 
methanol (Sigma). The membrane, gel, and associated filters were stacked in the 
appropriate sequence and soaked for 5 min in working transfer buffer while air pockets 
were carefully pressed or tapped out. 400 ul of Antioxidant Solution was added to the 
working transfer buffer just prior to the electrophoretic transfer which was performed at 
30 V for 1 h. 
To develop the membranes, a WesternBreeze® Chemiluminescent 
Immunodetection Kit (Invitrogen) was used. All proprietary reagents were obtained from 
Invitrogen unless otherwise indicated. The membranes were placed in separate clean 
polycarbonate trays and incubated with 5 ml Blocking Solution for 30 min at room 
temperature. Primary Antibody Solution was made by diluting Mouse Anti-Rabbit IgG 
(Santa Cruz Biotechnology) 1:1,000 in Blocking Solution. The primary antibodies were 
specific for either BNP, CRP, or TNNI. After blocking, the membranes were rinsed 
twice with 20 ml ddEbO — 5 min per rinse. Each membrane was then incubated with 10 
ml of Primary Antibody Solution for 24 h at 4°C. 
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After primary antibody incubation, the membranes were washed 4 times with 
20 ml Antibody Wash — 5 min per wash. Next, the membranes were incubated with 
10 ml of Secondary Antibody Solution for 1 h at room temperature. Afterward, the 
membranes were washed 4 times with 20 ml Antibody Wash — 5 min per wash. The 
membranes were then rinsed 3 times with 20 ml ddt^O — 2 min per rinse. The 
membranes were exposed to 2.5 ml Chemiluminescent Substrate for 5 minutes. Excess 
substrate was blotted off gently with clean filter paper and the arrays were placed into 
transparent plastic bags for imaging. The membranes photographed using the same 
imaging system as in the genetic array experiments. Images were analyzed by Quantity 
One for densitometry. 
Heart Function 
In these experiments, we characterized the functional response of the intact heart 
to acute cocaine exposure. The New Zealand White (NZW) rabbit (Oryctolagus 
cuniculus) was used for this part of the study. All animals were kept under temperature 
controlled conditions with automated 12 h light/dark cycles and allowed access to 
standard food pellets and water ad libitum. All animals were maintained by the Animal 
Care Director and Veterinarian at Old Dominion University's Department of Biological 
Sciences housing facility and treated humanely in accordance with federal regulations 
(IACUC protocol number 04-014; April 26, 2005). 
General anesthesia was induced by giving ketamine (40 mg/kg) and xylazine 
(5 mg/kg) intramuscular. After shaving the ventral neck and upper chest hairs, the 
animal was placed in the supine position. A longitudinal skin incision over the mid-line 
of the trachea was made with a number 10 scalpel. The left common carotid artery was 
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carefully isolated from the vagus nerve and surrounding connective tissues. A small 
incision was made and a Millar catheter (model SPR-524) (Millar Instruments) was 
inserted into the left ventricle via the left common carotid artery. This catheter has a 
specialized sensor tip designed for transducing mechanical signals from the 
myocardium. 
A Digi-Med Heart Performance Analyzer-x model 410 (Micro-Med) was 
connected to the Millar catheter. This machine and the accompanying software allows 
for the measurement of the following cardiac functional parameters: heart rate (HR) - the 
number of left ventricular contractions per minute; maximum pressure (MaxP) - the 
highest pressure within the left ventricle; end diastolic pressure (EDP) - the pressure 
within the left ventricle at the end of relaxation; (MinP) - the lowest pressure within the 
left ventricle; inotropy (dP/dt) - the rate of positive change in pressure with respect to 
time; lusitropy (-dP/dt) - the rate of negative change in pressure with respect to time; 
one-half relaxation (1/2R) - amount of time from peak tension to 50% of peak tension; 
duration of contraction (DCON) - amount of time spent in systole; and duration of 
relaxation (DREL) - amount of time spent in diastole. The technique of direct 
intraventricular catheterization via the common carotid artery has the advantage of being 
able to accurately measure heart functional parameters without the technical 
complications and physical trauma of opening the chest cavity. 
Baseline data (before the injection of cocaine or vehicle) was recorded for 10 min 
in order to establish a control for each animal. The animals were then injected with 
either 1 ml sterile isotonic saline (vehicle) or cocaine (2 mg/kg) reconstituted in 1 ml of 
sterile isotonic saline. After injection, data was recorded every 10 s for a total of 30 min 
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and then exported to an Excel spreadsheet. After data collection, the animal was 
euthanized via intravenous injection of saturated potassium chloride (Sigma) in water. 
The whole heart was carefully removed and weighed on an analytical mass balance. The 
left ventricle was then isolated from the rest of the heart tissue and divided into several 
sections for subsequent experiments. All sections were snap-frozen with liquid nitrogen 
and stored at -80°C until use. 
EXPERIMENTS WITH ECSTASY 
Dual-Luciferase Luminometry 
In these experiments, we observed the effects of ecstasy on NF-KB activity in 
cultured cardiac myocytes. Ecstasy is a schedule I substance with the Drug Enforcement 
Agency (DEA) of the United States and was obtained, stored, handled, and disposed of 
in accordance with federal, state, and University regulations by a DEA licensed 
investigator (Dr. Barbara Y. Hargrave). The same protocol as described in our cocaine 
experiments was used to maintain and treat the cells with the exception that on day 3, the 
following concentrations of MDMA were tested: 0 M, 1X10"6 M, IX10"5 M, IX10"4 M, 
1X1(T M, and 1X10"Z M. The drug was dissolved in enough cell culture media to 
achieve each concentration and 2 ml of each dose was gently added to the appropriate 
wells. To examine the effects of IKB overexpression on ecstasy induced NF-KB activity, 
cells co-transfected with IKB DNA were stimulated with either 0 M, 1X10"3 M, or 
1X1 (TM MDMA. For a summary of the transfection and drug dosage scheme, see 
Tables 4 and 5. 
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TABLE 4. Transfection Protocol and Drug Dosage Scheme for H9c2 
Cells Transfected With NF-KB Reporter and Stimulated With Ecstasy 
Well# 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Ecstasy 
(M) 
0 
0 
1X10"6 
1X10"6 
1X10"5 
1X10"5 
1X10"4 
1X10"4 
1X10"3 
1X10"3 
IX10"2 
1X10"2 
NF-KB 
(re) 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
IKB 
(re) 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
pRL-SV40 
(re) 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
PCMV 
(re) 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
TABLE 5. Transfection Protocol and Drug Dosage Scheme for H9c2 
Cells Co-Transfected With NF-KB Reporter and IKB Overexpression 
Vector and Stimulated With Ecstasy 
Well# 
1 
2 
3 
4 
5 
6 
Ecstasy 
(M) 
0 
0 
1X10"3 
1X10"3 
1X10"2 
1X10"2 
NF-KB 
(re) 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
IKB 
G*g) 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
pRL-SV40 
(re) 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
PCMV 
(re) 
0 
0 
0 
0 
0 
0 
Reactive Oxygen Species Assay 
In these experiments, we observed the effects of ecstasy on ROS generation in 
cultured cardiac myocytes. The same protocol as described with our cocaine experiments 
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was used to maintain and treat the cells with the exception that on day 2, the following 
concentrations of MDMA were tested: 1X10"4 M, 1X10"3 M, and 1X10"2 M. The drug 
was dissolved in enough Hank's Media to achieve each concentration and 2 ml of each 
dose was gently added to the appropriate wells. Just prior to drug exposure, each well 
was photographed to obtain a baseline signal. This allowed each well to serve as its own 
0 M control. The remainder of the protocol was followed as described in our cocaine 
experiments. 
Intracellular Calcium Assay 
In these experiments, we observed the effects of ecstasy on intracellular Ca2+ 
levels in cultured cardiac myocytes. The same protocol as described with our cocaine 
experiments was used to maintain and treat the cells with the exception that on day 2, the 
following concentrations of MDMA were tested: 1X10"4 M, 1X10"3 M, and 1X10"2 M. 
The drug was dissolved in enough Hank's Media to achieve each concentration and 2 ml 
of each dose was gently added to the appropriate wells. Just prior to drug exposure, each 
well was photographed to obtain a baseline signal. This allowed each well to serve as its 
own 0 M control. The remainder of the protocol was followed as described in our 
cocaine experiments. 
Gene Array 
In these experiments, we characterized the genetic response of H9c2 cells after 
exposure to ecstasy. As in our experiments with cocaine, GEArray™ Q Series Kits 
(SuperArray) were used for assessing the transcription levels of certain genes after 
exposure to ecstasy. A 96-well array containing genes important to cardiovascular 
pathology was used — Mouse Cardiovascular Disease Biomarkers. A different 96-well 
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array containing genes important to cardiovascular toxicology was also used — Mouse 
Stress & Toxicity Pathway Finder. Some of the genes on the arrays are dependent on 
NF-KB activity. 
The same protocol as described with our cocaine experiments was used to 
maintain and treat the cells with the exception that on day 1, after becoming 
approximately 85% confluent, each T-75 flask was treated with either 0 M or IX10"3 M 
MDMA for 24 h. The drug was dissolved in enough cell culture media to achieve each 
concentration and 10 ml of each dose was gently added to the appropriate flask. The 
remainder of the protocol was followed as described in our cocaine experiments. 
Immunohistochemistry 
Since our gene array data indicated that MDMA could increase transcription of 
certain genes important to inflammation and hypertrophy, the objective of these 
experiments was to measure the expression of certain genes on the array at the protein 
level within rabbit myocardium after acute MDMA exposure. In situ hybridization 
immunohistochemistry allows for localization and quantification of specific proteins in 
tissue sections. Specimens collected from our heart function experiment were processed 
for the detection of brain natriuretic peptide (BNP), C-reactive protein (CRP), and 
troponin 3 (Tnni3). These proteins are important biomarkers for myocardial 
inflammation and hypertrophy. 
The specimens were fixed in 10% formalin (pH 7.4) (Sigma) for 2 h at 4°C, 
followed by 25% sucrose (Sigma) infiltration overnight at 4°C. Next, the tissues were 
embedded in Optimal Cutting Temperature Compound (Tissue-Tek) and sectioned at 
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5 urn thickness on a cryostat (American Optical) at -20°C. The sections were picked up 
on electrostatically treated microscope slides (Fisher) and allowed to air dry for 1 h at 
room temperature. 
The HistoMark® Biotin Streptavidin-HRP System (Kirkegaard & Perry 
Laboratories) was used to stain the sections. All proprietary reagents were obtained from 
Kirkegaard & Perry Laboratories unless otherwise indicated. All steps were performed at 
room temperature. The slides were rinsed for 15 min in PBS (pH 7.4) and then blocked 
for endogenous peroxidase activity by exposure to Universal Blocking Solution for 5 
min. After shaking off excess fluid, the slides were exposed to Rabbit Serum Block for 
15 min. Primary and secondary antibody solutions were made to a concentration of 10 
ug/ml in PBS. For primary antibody exposure, the slides were incubated with Mouse 
Anti-Rabbit IgG (Santa Cruz Biotechnology) for 30 min. The primary antibodies were 
specific for either BNP, CRP, or TNNI. Afterward, the slides were rinsed in PBS for 
5 min. For secondary antibody exposure, the slides were incubated with Biotinylated 
Goat Anti-Mouse IgG for 30 min. Next, the slides were rinsed in PBS for 5 min and then 
incubated with Streptavidin-Peroxidase Solution for 30 min. After a final rinse in PBS 
for 5 min, the slides were exposed to True Blue Substrate for 10 min. The slides were 
then rinsed in sterile protease-free water (HyClone) for 2 min, dehydrated on a slide 
warmer, and coverslipped with Permount™ mounting medium (Fisher). Target protein 
specific staining appeared as light blue colorings within each section. The sections were 
digitally photographed under 100X magnification. Images were analyzed by Quantity 
One for densitometry. 
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Western Blot 
As an additional approach to characterizing protein level expression, Western 
blots for array-specific proteins were performed. Cultured H9c2 cells treated with 
MDMA and myocardial tissues collected from acutely exposed rabbits in our functional 
experiments were both processed for this technique. The same protocol as described with 
our cocaine experiments was used to maintain and treat the cells with the exception that 
on day 1, the following concentrations of MDMA were tested: 0 M, 2 uM, or 1 mM. The 
drug was dissolved in enough cell culture media to achieve each concentration and 10 ml 
of each dose was gently added to the appropriate flask. Primary antibodies for the 
following proteins were used: VCAM-1 or iNOS. Since our ELISA experiments for 
NF-KB indicated the possibility of increased activity at earlier time points and different 
concentrations of MDMA, Westerns for VCAM-1 and iNOS were performed at those 
corresponding time points and concentrations. For rabbit myocardial tissues from our 
functional experiments, primary antibodies for the following proteins were used: BNP 
and CRP. The remainder of the protocol was followed as described in our cocaine 
experiments. 
ELISA 
The objective of these experiments was to observe the effects of MDMA on 
NF-KB activity in cultured H9c2 cells and in rabbit myocardium after acute exposure. 
Our luminometry experiments revealed that 1 mM MDMA was the minimal dose 
required for activating NF-KB in H9c2 cells after 24 h of exposure. Therefore, we 
decided to test this particular dose, a maximal dose of 10 mM, and a more clinically 
relevant concentration of 2 uM to examine their effects on NF-KB activity at earlier time 
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points of exposure. We also examined rabbit myocardium from acutely treated animals 
from our functional experiments. 
The H9c2 cells were grown and maintained as described in our luminometry 
experiments. On day 1, with the aid of a hemacytometer, approximately 1,000,000 cells 
were plated onto each well of a sterile 6-well culture plate (Corning). Enough fresh 
media was added to adjust the final volume to 5 ml in each well. The plate was then 
returned to the incubator for 24 h. On day 2, the overlying media was removed and 
discarded. Each well was treated with either 0 M, 2 uM, 1 mM, or 10 mM MDMA. The 
drug was dissolved in enough cell culture media to achieve each concentration and 3 ml 
of each dose was gently added to the appropriate wells. The plate was then returned to 
the incubator for either 3, 6, or 12 h. 
After treatment, the drug solution was removed and discarded. Nuclear proteins 
were isolated using a nuclear extraction kit (Panomics). All proprietary reagents were 
obtained from Panomics unless otherwise indicated. Working Buffer A for each sample 
was made by mixing 1 ml of Buffer A with 10 ul dithiothreitol (DTT), 10 ul Protease 
Inhibitor Solution, 10 ul Phosphatase Inhibitor I Solution, and 10 ul Phosphatase 
Inhibitor II Solution. Working Buffer B was made by mixing 1 ml of Buffer B with 
10 ul DTT, 10 ul Protease Inhibitor Solution, 10 ul Phosphatase Inhibitor I Solution, and 
10 ul Phosphatase Inhibitor II Solution. Each well was washed twice with 1 ml of PBS 
(pH 7.4). 250 ul working Buffer A was added to each well. The plate was put on ice and 
rocked on a platform for 10 min at 200 RPM. Afterward, each well was scraped for 30 s 
with a sterile cell scraper and the suspension transferred into separate sterile 
microcentrifuge tubes. The tubes were centrifuged at 14,000X for 3 min in a 7°C cold 
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room. The supernatant (cytosolic fraction) was removed while the pellet (nuclear 
fraction) was placed on ice. 50 ul working Buffer B was added to each tube. The tubes 
were vortexed on high for 10 s and then incubated on ice for 1 h with gentle hand 
agitation every 20 min. The tubes were then centrifuged at 14,000X for 5 min in a 7°C 
cold room. The supernatant (containing nuclear proteins) was transferred into new 
separate sterile microcentrifuge tubes and stored at -80°C until use. Protein concentration 
for each sample was determined using the Bradford assay. 
To isolate nuclear proteins from tissue samples, a slightly different protocol was 
followed using the same nuclear extraction kit from Panomics. Working Buffer A and 
working Buffer B were made as previously described, but scaled up to accommodate the 
volumes needed for tissue processing. All tissue samples were cut into small pieces with 
a clean razor blade and 0.5 g was weighed out and place into separate sterile 15 ml 
conical tubes. The samples were homogenized on ice in a 7°C cold room. 1.5 ml of 
working Buffer A was added to each tube and the contents were again homogenized on 
ice in a 7°C cold room. The samples were then incubated on ice for 20 min. Next, the 
samples were centrifuged at 850X for 10 min at 4°C. After removal of the supernatant, 
1.5 ml of working Buffer A was added to each tube and the contents were homogenized 
on ice in a 7°C cold room. The samples were then transferred to separate sterile 
microcentrifuge tubes and incubated on ice for 20 min. Afterward, the samples were 
centrifuged at 14,000X for 3 min in a 7°C cold room. The supernatant (cytosolic 
fraction) was removed while the pellet (nuclear fraction) was placed on ice. 150 ul 
working Buffer B was added to each tube. The tubes were vortexed on high for 10 s and 
then incubated on ice for 1 h with gentle hand agitation every 20 min. The tubes were 
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then centrifuged at 14,000X for 5 min in a 7°C cold room. The supernatant (containing 
nuclear proteins) was transferred into new separate sterile microcentrifuge tubes and 
stored at -80°C until use. Protein concentration for each sample was determined using 
the Bradford assay. 
A TransBinding™ NF-KB Assay Kit (Panomics) was used to measure the amount 
of NF-KB activity in each sample. This ELISA based method utilizes a special 96-well 
Assay Plate coated with NF-KB binding consensus DNA sequence. All proprietary 
reagents and plates were obtained from Panomics unless otherwise indicated. An initial 
200 ul of Wash Buffer was added to each well and the Assay Plate was incubated for 
20 min at room temperature. The wells were then washed 3 times with 200 ul of Wash 
Buffer. Next, 40 ul of Binding Buffer was added to each well. Nuclear extracts were 
diluted to an equal total protein concentration of 2.0 ug/ul using Nuclear Extract 
Dilution Buffer. 10 ul of diluted nuclear extracts were added to the appropriate wells and 
the Assay Plate was incubated for 1 h at room temperature with constant agitation on a 
rocking platform. The wells were then washed 3 times with 200 ul of Wash Buffer. 
Primary antibody specific for NF-KB p50 was diluted 1:100 in Antibody Dilution Buffer. 
100 ul of the diluted primary antibody was added to each well and the Assay Plate was 
incubated for 1 hour at room temperature with constant agitation on a rocking platform. 
The wells were then washed 3 times with 200 ul of Wash Buffer. Next, anti-rabbit 
horseradish peroxidase (HRP)-conjugated secondary antibody was diluted 1:1,000 in 
Antibody Dilution Buffer. 100 ul of the diluted secondary antibody was added to each 
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well and the Assay Plate was incubated for 1 h at room temperature with constant 
agitation on a rocking platform. The wells were then washed 3 times with 
200 ul of Wash Buffer. Afterward, 100 ul of Substrate Solution was added to each well 
and the Assay Plate was wrapped in foil and incubated for 10 min at room temperature. 
Finally, 100 ul of Stop Solution was added and the Assay Plate was read within 5 min 
for A450 nm on a BMG Fluostar spectrophotometer (BMG Labtechnologies). 
In a related set of experiments, we examined the effects of 2 uM and 1 mM 
MDMA on NF-KB activity in H9c2 cells at the 15, 30, and 60 min time points. An 
updated Transcription Factor ELISA Kit (Panomics) was used for this experiment. 
Myocardial tissue samples from our functional experiments and H9c2 cells from our 
10 mM MDMA experiments were also analyzed using this kit. Unlike the previous 
protocol, this ELISA based method utilizes a separate Sample Plate for the initial mixing 
of reagents and a special 96-well Assay Plate coated with streptavidin. A biotinylated 
oligonucleotide containing an NF-KB binding consensus DNA sequence is reacted in 
solution with samples containing unknown amounts of NF-KB protein. All proprietary 
reagents and plates were obtained from Panomics unless otherwise indicated. Binding 
Buffer Master Mix was created for each well by combining 10 ul Binding Buffer with 
2.5 |al TF-Specific Probe and 27.5 ul sterile nuclease-free water. 40 ul of Binding Buffer 
Master Mix was added to each well of the Sample Plate. Nuclear extracts were diluted to 
an equal total protein concentration of 2.0 ug/ul using Nuclear Extract Dilution Buffer. 
10 ul of diluted nuclear extracts were added to the appropriate wells and the Sample 
Plate was incubated for 30 min at room temperature with constant agitation on a rocking 
platform. The Assay Plate was prepped to capture TF-DNA complexes by washing 3 
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times with 200 ul of Wash Buffer. Afterward, 45 ul of sample solution from each well of 
the Sample Plate was added to the corresponding well of the Assay Plate. The Assay 
Plate was then incubated for 1 h at room temperature with constant agitation on a 
rocking platform. The wells were then washed 3 times with 200 JLXI of Wash Buffer. 
Primary antibody specific for NF-KB p50 or p65 was diluted 1:200 in Antibody Dilution 
Buffer. 100 ul of the diluted primary antibody was added to each well and the Assay 
Plate was incubated for 1 h at room temperature with constant agitation on a rocking 
platform. The wells were then washed 3 times with 200 ul of Wash Buffer. Next, anti-
rabbit HRP-conjugated secondary antibody was diluted 1:200 in Antibody Dilution 
Buffer. 100 ul of the diluted secondary antibody was added to each well and the Assay 
Plate was incubated for 1 h at room temperature with constant agitation on a rocking 
platform. The remainder of the protocol was followed as described for the previous kit. 
Heart Function 
In these experiments, we characterized the functional response of the intact heart 
to acute ecstasy exposure. As in our cocaine experiments, the New Zealand White 
(NZW) rabbit (Oryctolagus cuniculus) was used for this part of the study. The same 
animal care and surgical procedures were followed as described previously. All animals 
were maintained by the Animal Care Director and Veterinarian at Old Dominion 
University's Department of Biological Sciences housing facility and treated humanely in 
accordance with federal regulations (IACUC protocol number 08-011; September 18, 
2008). 
Baseline data was recorded for 10 min in order to establish a control for each 
animal. The animals were then injected with either 1 ml sterile isotonic saline (vehicle) 
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or 2 mg/kg ecstasy reconstituted in 1 ml of sterile isotonic saline. To determine if nitric 
oxide synthase (NOS) inhibition alters the functional changes induced by ecstasy, some 
animals were given 10 mg/kg NG-nitro-L-arginine methyl ester (L-NAME) reconstituted 
in 1 ml of sterile isotonic saline for 10 minutes prior to ecstasy exposure. Data was 
recorded every 10 seconds for a total of 15 min and then exported to an Excel 
spreadsheet. The remainder of the protocol was followed as described in our cocaine 
experiments. 
RESULTS 
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EXPERIMENTS WITH COCAINE 
Dual-Luciferase Luminometry 
NF-KB activity is important to many myocardial pathophysiological processes 
including inflammation and hypertrophy. The purpose of these experiments was to 
observe the effects of cocaine on the NF-KB response in cultured H9c2 cells. This cell 
line provides a valuable in vitro model for the study of various drugs on cardiac 
myocytes. Drug metabolizing enzymes CYP1A1, CYP1B1, CYP2B1, CYP2B2, 
CYP2E1, and CYP2J3 are expressed in both H9c2 and adult rat heart cells.128 Dual-
luciferase luminometry allows for internal normalization of target gene activity to a 
constitutively active reporter gene. The normalized ratiometric data minimizes the 
effects of certain subjective errors and allows for a more accurate compilation of data 
obtained during different trial runs. 
Figure 1 shows that 1X10"3 M and 1X10"2 M cocaine at 24 h significantly 
activated NF-KB in cultured H9c2 cells 24 h after exposure and the high dose of 
1X10"2 M cocaine significantly activated NF-KB despite the presence of IKB 
overexpression (Figure 2). These results indicate that in cultured cardiac myocytes, 
cocaine activates NF-KB in a dose-dependent manner and that IKB overexpression is not 
sufficient to block this response at the high dose of IX10"2 M cocaine. 
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Figure 1. NF-KB activity in H9c2 cells stimulated with cocaine for 24 h. (n = 5 
separate experiments). Cells in the 0 M wells were exposed to media only and served as 
controls. Data are stated as mean relative luminometry unit (RLU) ratio (experimental 
reporter signal/control reporter signal) ± SD. * = p < 0.05 vs. 0 M. 
1.2 
0 0.8 
1 0.6 
2 0.4 
0.2 
. * 
0 M + IkB 10(-2) M + IkB 
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Figure 2. NF-KB activity in H9c2 cells co-transfected with NF-KB reporter and IKB 
overexpression vector and stimulated with cocaine for 24 h. (n = 5 separate 
experiments). Cells in the 0 M + IKB wells were exposed to IKB overexpression 
vector in media only and served as controls. Data are stated as mean RLU ratio ± SD. 
* = p < 0.05 vs. 0 M + IKB. 
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Reactive Oxygen Species 
Evidence in rats indicates that cocaine can reduce intracellular antioxidant 
potential and increase the risk for ROS generation in the myocardium.59'63 ROS can 
damage biological macromolecules and cellular structures. ROS are also known to 
activate NF-KB. The purpose of these experiments was to observe the effects of cocaine 
on ROS generation in cultured cardiac myocytes. We loaded H9c2 cells with the ROS 
indicator 2',7'-dichlorofluorescin diacetate and measured ROS generation in response to 
cocaine using confocal microscopy. We found that H9c2 cells began to generate 
significant amounts of ROS relative to background upon exposure to 1X10"3 M and 
1X10" M cocaine, causing a 77% and 69% increase respectively, at 5 min (Table 6). 
This finding indicates that cocaine can significantly increase intracellular ROS in 
cultured cardiac myocytes, and since ROS can activate NF-KB, it is possible that cocaine 
activates NF-KB by increasing the net generation of this free radical. 
TABLE 6. Mean Intensity of H9c2 Cells Loaded With 2',7'-Dichlorofluorescin 
Diacetate (ROS) Indicator and Stimulated With Cocaine 
Drug 
Concentration 
1X10"4M 
1X10"3M 
1X10"2M 
Control Signal 
203.0 ±62.7 
364.6 ± 226.3 
392.3 ±188.5 
ROS Signal 
2 min post-drug 
222.5 ± 120.4 
582.1 ±358.2* 
564.0 ± 292.2* 
ROS Signal 
5 min post-drug 
223.6 ±138.4 
645.0 ±438.1* 
662.3 ± 404.0* 
* = p < 0.05 vs. Control Signal, (n = 3). 
Cocaine-induced catecholaminergic stimulation is also known to elevate both 
intracellular Ca2+ and to increase contractility of the left ventricle.29 To determine if the 
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cocaine induced increase in intracellular Ca was associated with ROS generation, we 
pre-treated H9c2 cells with either the antioxidant N-acetylcysteine (NAC), or the Ca 
channel blockers verapamil, or nifedipine, or the P-adrenergic receptor blocker nadolol, 
and then exposed the cells to 1X10" M cocaine. Pre-treatment with 1 mM NAC, blunted 
the increase in ROS normally induced by exposure to 1X10" M cocaine, causing a 22% 
decrease in the ROS signal at 5 min. Pre-treatment with 10 uM nifedipine also blunted 
the increase in ROS normally induced by 1X10" M cocaine at 2 min, however, this 
effect was transient and not observed at 5 min. Pre-treatment with either 10 uM 
verapamil or 10 uM nadolol did not affect the increase in ROS normally induced by 
1X10"2 M cocaine at either 2 min or 5 min. These findings suggest that antioxidant pre-
treatment is more effective in reducing ROS generation than Ca2+ channel antagonist or 
P-adrenergic blockade. Table 7 summarizes the results of these experiments. 
TABLE 7. Mean Intensity of H9c2 Cells Loaded With 2',7'-Dichlorofluorescin 
Diacetate (ROS) Indicator, Pre-Treated With Various Agents, and Stimulated With 
Cocaine 
Drug Control Signal ROS Signal ROS Signal 
Concentration 2 min post- 5 min post-
cocaine cocaine 
lX10" 2 M+lmMNAC 295.8 ±111.0 No Data 230.8 ±160.7 
1X10"2 M + 10 uM verapamil 261.2 ± 140.0 371.0 ± 165.6* 399.1 ± 143.4* 
1X10"2M+ 10 \xM nifedipine 187.3 ±69.9 259.6 ±112.8 281.1 ± 105.3* 
1X10"2M+ 10 uM nadolol 120.5 ±81.1 178.8 ±119.8* 194.7 ±154.5* 
p < 0.05 vs. Control Signal, (n = 3). 
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Dual-Luciferase Luminometry With Antioxidant Pre-Treatment 
We tested the efficacy of antioxidant pre-treatment in reducing the NF-KB 
response induced by 1X10"2 M cocaine. Since cocaine significantly increased ROS in 
our confocal experiments and ROS are implicated in NF-KB activation, we felt that these 
experiments were warranted. Figure 3 shows the NF-KB activity in cultured H9c2 cells 
exposed to 1X10"2 M cocaine, or pre-treated with the antioxidants glutathione (1 mM) 
and/or NAC (1 mM) then exposed to cocaine. While pre-treatment with glutathione 
caused a 33% decrease in NF-KB activity, this change was not statistically different from 
cells exposed to cocaine alone. However, in cells pre-treated with NAC, then exposed to 
cocaine, there was a significant decrease in NF-KB activity compared to cocaine 
treatment alone. When cells were pre-treated with both glutathione and NAC, there was 
an 83% inhibition of the cocaine induced activation of N F - K B . 
These results indicate that in cultured cardiac myocytes, the ROS generated by 
cocaine are responsible for NF-KB activation and that NAC is more effective than 
glutathione in reducing this response. These findings are interesting since NAC exerts its 
1 9Q 
antioxidant effects by acting as a precursor for replenishing glutathione. One would 
therefore expect that pre-treatment with glutathione itself would be more effective in 
reducing NF-KB activity compared to pre-treatment with NAC. A possible explanation 
for the effectiveness of NAC may be that NAC enters the cell more efficiently than 
glutathione due to its lower molecular weight. 
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Figure 3. NF-KB activity in H9c2 cells pre-treated with antioxidant for 15 min and 
stimulated with cocaine for 6 h. (n = 10 separate experiments). Cells in the 0 M wells 
were exposed to media only and served as controls. Data are stated as mean RLU 
ratio ± SD. * = p < 0.05 1X10"2 M Coc vs. 0 M Coc and 1X10"2 M Coc + 1 mM Glut vs. 
0 M Coc. # = p < 0.05 1X10"2 M Coc + 1 mM NAC vs. 1X10"2 M Coc and 1X10"2 M 
Coc + 1 mM Glut + 1 mM NAC vs. 1X10"2 M Coc. 
,2+ . 
Intracellular Calcium Experiments 
In cardiac myocytes, intracellular Caz^ is an important ion involved with second 
messenger signaling and the excitation-contraction mechanism. Ca overload has been 
linked to myocardial apoptosis, hypertrophy, and dysfunction. Our previous studies 
suggested that antioxidant pre-treatment, but not Ca channel blocker pre-treatment, 
reduced the cocaine induced generation of ROS. The data suggested that the mechanism 
of ROS generation by cocaine may not involve the increase in intracellular Ca2+. 
However, cocaine is known to increase contractility in the heart which requires elevated 
intracellular Ca2+. To determine if cocaine increased intracellular Ca +, we exposed 
H9c2 cells to 1X10"5 M, 1X10"4 M, 1X10"3 M, and 1X10"2 M cocaine and measured 
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intracellular Ca2+ using the fluorescent Ca2+ indicator fluo-3 and confocal microscopy. 
Cocaine at concentrations of 1X10"4 M, IX10"3 M, and 1X10"2 M significantly elevated 
intracellular Ca2+ at both 2 and 5 min (Table 8). This finding indicates that cocaine can 
significantly elevate intracellular Ca in cultured cardiac myocytes. 
TABLE 8. Mean Intensity of H9c2 Cells Loaded With the Intracellular Ca2+ 
Indicator Fluo-3 and Stimulated With Cocaine 
Drug Control Signal Ca2+ Signal Ca2+ Signal 
Concentration 2 min post- 5 min post-
cocaine cocaine 
1X10~5M 70.2 ± 39.2 75.9 ±27.6 75.1 ±27.5 
1X10"4M 92.9 ±50.9 106.6 ±68.2* 107.7 ±68.0* 
1X10"3M 134.1 ±66.9 219.7 ±185.9* 216.5 ±176.5* 
1X10"2M 83.2 ±32.2 206.6 ±183.3* 600.2 ± 728.7* 
* = p < 0.05 vs. Control Signal, (n = 3). 
Since the extracellular fluids surrounding cardiac myocytes is an important source 
-\\ 9-1-
of intracellular Ca by way of voltage-gated Ca channel conductance, and ROS can 
damage internal Ca2+ storage compartments causing release of free Ca2+ into the cytosol, 
we tested the efficacy of Ca2+ channel blocking and antioxidant pre-treatment on 
reducing the cocaine-induced elevation of intracellular Ca in cultured cardiac 
myocytes. 
Pre-treatment of H9c2 cells with the Ca channel blockers verapamil (10 uM) 
or nifedipine (10 uM) decreased the intracellular Ca2+ levels normally induced by 
1X10"4 M cocaine at both 2 and 5 min (Table 9). In the previous experiment (Table 8), 
the 1X10"4 M concentration of cocaine caused a 16% increase in intracellular Ca2+ at 
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5 min, and the increase was statistically significant over baseline. In this experiment, 
using the same concentration of cocaine, 10 uM verapamil pre-treatment followed by 
1X10"4 M cocaine led to only a 9% increase of intracellular Ca2+ at 5 min, while 10 uM 
nifedipine pre-treatment followed by 1X10"4 M cocaine led to a 4% decrease of 
intracellular Ca2+ at 5 min. These changes were statistically no higher or lower than 
9+ 
baseline, implying that Ca levels remained at baseline despite the presence of 
1X10"4M cocaine. Pre-treatment with 10 \xM verapamil had a similar effect by 
9+ "3 
decreasing the intracellular Ca levels normally induced by 1X10" M cocaine at 2 min, 
however, this effect was transient and not maintained to the 5 min mark (Table 9). 
94- 94-
Although both compounds block Ca conductance through the L-type Ca channel in 
the heart, the differences in efficacy between verapamil and nifedipine may be attributed 
to the different binding sites and binding affinities of each drug for the channel.130'131 
9+ 
In contrast to the Ca channel blockers, pre-treatment with the antioxidant 1 mM 
NAC decreased the intracellular Ca2+ levels normally induced by both 1X10"4 M and 
1X10" M cocaine at 2 and 5 min (Table 10). Since neither verapamil nor nifedipine 
showed this effect at the 1X10' M concentration of cocaine, these results suggest that 
increasing cellular antioxidant capacity may be more effective than Ca2+ channel 
blockade in protecting against cocaine-induced intracellular Ca2+ elevation in cultured 
cardiac myocytes. 
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TABLE 9. Mean Intensity of H9c2 Cells Loaded With the Intracellular Ca2+ 
Indicator Fluo-3, Pre-Treated With Ca2+Channel Blockers, and Stimulated 
With Cocaine 
Drug Control Signal Ca2+ Signal Ca2+ Signal 
Concentration 2 min post- 5 min post-
cocaine cocaine 
1X10"4 M + 10 nM verapamil 116.8 + 48.9 118.1 ±54.8 127.4 ±72.2 
1X10"3M+10 nM verapamil 151.3 ±74.5 169.5 ± 86.7 259.5 ± 134.0* 
1X10"2M+ 10 \M verapamil 133.3 ±83.3 160.0 ±68.6* 194.4 ±70.6* 
1X10"4M+10 nM nifedipine 99.0 ±63.4 94.0 ±55.6 94.8 ±55.8 
1X10"3M+10 ^M nifedipine 147.1 ±67.7 132.5 ± 56.7* 132.9 ±55.0* 
1X10"2 M + 10 \M nifedipine 223.0 ± 179.5 302.1 ± 206.3* 412.7 ± 392.5* 
* = p < 0.05 vs. Control Signal, (n = 3). 
TABLE 10. Mean Intensity of H9c2 Cells Loaded With the Intracellular Ca2+ 
Indicator Fluo-3, Pre-Treated With NAC, and Stimulated With Cocaine 
__ __ 
Drug Control Signal Ca Signal Ca Signal 
Concentration 2 min post- 5 min post-
cocaine cocaine 
1X10"5M+1 mMNAC 140.0 ± 74.0 145.2 ±114.4 149.4 ±73.5 
1X10"4M+1 mMNAC 157.2 ±94.1 147.5 ± 74.3 170.1 ±99.6 
1X10"3M+1 mMNAC 201.9 ±131.4 187.1 ± 107.2 203.5 ±102.3 
1X10"2M+1 mMNAC 122.4 ±104.1 233.3 ±214.2* 440.0 ±440.6* 
* = p < 0.05 vs. Control Signal, (n = 3). 
Gene Array 
Our luminometry and confocal experiments revealed that 1X10" M and 1X10" M 
cocaine significantly activates NF-KB, and that 1X10"4 M, IX10"3 M, and 1X10"2 M 
cocaine significantly elevates intracellular Ca in cultured cardiac myocytes. Both of 
these effects could potentially alter the transcription of genes that are detrimental to 
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cardiac homeostasis. Therefore, we characterized the genetic response of cocaine treated 
H9c2 cells and the rabbit myocardium exposed to cocaine in vivo using arrays containing 
genes associated with cardiovascular disease and toxicity. 
Cultured H9c2 cells treated with 1X10"2 M cocaine for 24 h and rabbit left 
ventricular heart tissue exposed to cocaine (2 mg/kg) in vivo exhibited alterations in 
mRNA expression levels of genes involved with cardiovascular disease and Ca 
signaling (Tables 11 and 12). Signal ratios appeared to be stronger in the Ca signaling 
array for rabbit heart tissue compared to the H9c2 cells and in some cases, genes not 
activated in H9c2 cells were found to be active in the rabbit heart. For example, 
BRCA-1 and Calb2, genes involved with hypertrophy and anti-apoptosis, were both 
upregulated in rabbit heart tissue, but not in H9c2 cells. This may be due to differences 
in cell type and environment (cardiac myoblasts in vitro vs. adult cardiac myocytes in 
vivo), or differences in duration of cocaine exposure (24 h vs. 30 min). 
In the cardiovascular disease biomarker array, cocaine upregulated genes 
associated with apoptosis, inflammation, heart failure, and cardiac remodeling in H9c2 
cells (Table 11). Upregulation of the KCNA5 gene was verified by temperature gradient 
RT-PCR (Figure 4). Increased expression of this gene is associated with cardiac 
rhythmic abnormalities because potassium channels are important to the repolarization 
phase of the cardiac action potential.116 These results indicate that the detrimental effects 
of cocaine extend to the genetic level. Cocaine also upregulated pro-survival and growth 
suppressive genes, implying that compensatory mechanisms may be activated in 
response to the hypoxia caused by vasoconstriction by this drug. For example, if cocaine 
causes coronary artery vasoconstriction which leads to decrease flow of blood and 
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decreased nutrient delivery to the myocardium, then elevated expression of hexokinase 2 
(HK2) is a compensatory action since this enzyme works to increase the flow of glucose 
into cells.132 It is interesting that cocaine increased the expression of N F K B I . This shows 
that cocaine both activates NF-KB and increases the amount of the p50 subunit itself so 
that more NF-KB can be made, a possible mechanism for amplifying the NF-KB signal. 
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TABLE 11. Genes Affected by Cocaine in H9c2 Cells and Rabbit Heart: 
Mouse Cardiovascular Disease Biomarkers Array 
Additional Information 
Genes associated with 
apoptosis 
Genes associated with 
inflammation 
Genes associated with 
infarction, heart failure 
and cardiac remodeling 
Gene 
TNFa (tumor necrosis 
factor alpha) 
Fas 
CD40L 
FasL 
CRLF1 (cytokine 
receptor-like factor 1) 
N F K B I (p50) 
Timp (matrix 
metalloproteinase 
inhibitor) 
PPARy (peroxisome 
proliferator-activated 
receptor gamma) 
Tnni3 (troponin I type 3) 
ANP (atrial natriuretic 
peptide) 
CRP (c-reactive protein) 
BNP (brain natriuretic 
peptide) 
iNOS (inducible nitric 
oxide synthase) 
Signal Ratio 
H9c2 Cells 
» 1 0 
1.7 
» 1 0 
10.7 
6.3 
5.1 
10.7 
11.2 
5.1 
2.3 
» 1 0 
14.2 
» 1 0 
Signal Ratio 
Rabbit Heart 
2.5 
4.9 
4.1 
» 1 0 
2.6 
6.1 
6.4 
3.2 
1.5 
8.0 
5.4 
13.1 
8.0 
Genes from the Mouse Cardiovascular Disease Biomarkers array. 
Signal ratio = [(target geneexp-blankeXp)/(GAPDHexp-blankeXp)]/[(target genecontroi-
blankcontroO^GAPDHcontroi-blankcontroi)]- » 1 0 = a large positive response with a low 
control signal. 
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TABLE 12. Genes Affected by Cocaine in H9c2 Cells and Rabbit Heart: 
Mouse cAMP/Ca2+ Signaling Pathway Finder Array 
Additional Information Gene Signal Ratio Signal Ratio 
H9c2 Cells Rabbit Heart 
Genes associated with Adrbl (beta 1 adrenergic 2.0 6.1 
cardiac hypertrophy receptor) 
AHR (ary 1-hydrocarbon 1.7 3.5 
receptor) 
ANG (angiotensinogen) 1.6 2.9 
BRCA-1 (breast cancer 1 1.7 4.0 
protein) 
Ode (ornithine 1.1 3.8 
decarboxylase) 
Genes associated with 
growth suppression 
Genes associated with 
anti-apoptosis 
SMST (somatostatin) 
SSTR2 (somatostatin 
receptor subtype 2) 
Calbl (calbindin 1) 
Calb2 (calbindin 2) 
2.0 
2.2 
2.3 
1.3 
10.4 
8.1 
2.0 
» 1 0 
Genes associated with CRH (corticotropin 0.9 3.1 
heart failure releasing hormone) 
KCNA5 (voltage-gated 2.3 8.4 
potassium channel, shaker-
related subfamily 5 
Gene associated with 
glucose metabolism 
Gene associated with 
apoptosis 
HK2 (hexokinase 2) 
TNFa (tumor necrosis 
factor alpha) 
1.9 
1.3 
» 1 0 
3.0 
Genes from the Mouse cAMP/Ca Signaling Pathway Finder array. 
Signal ratio = [(target geneexp-blankexp)/(GAPDHexp-blankexp)]/[(target genecontroi-
blankcontroi)/(GAPDHcontroi-blankcontroi)]- » 1 0 = a large positive response with a low 
control signal. 
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Figure 4. Temperature gradient RT-PCR for KCNA5 gene rabbit heart. Lane 4 optimal 
annealing temperature 59.1°C. KCNA5 signal was normalized to GAPDH 
(housekeeping gene) signal. Semi-quantitative densitometry analysis indicated that 
KCNA5 mRNA was increased in the cocaine group compared to the placebo group. Left 
= placebo. Right = cocaine. 
Western Blot 
The previously described gene array experiments (Tables 11 and 12) indicated that 
the mRNA transcript levels of certain genes are affected by cocaine. Therefore, the 
purpose of the next experiments was to measure the protein level expression of array-
specific genes in cocaine treated cardiac myocytes. BNP, CRP, and Tnni3 are known to 
be upregulated during heart failure. These genes were also upregulated in the array 
experiments. We therefore performed Western blots for these proteins in cultured H9c2 
cells exposed to 1X10"2 M cocaine for 24 h. The results indicated that there were no 
significant differences in BNP, CRP, or Tnni3 expression compared to 0 M control. 
Immunoreactive bands did not resolve near the appropriate molecular weight markers for 
any of these proteins. These results suggest that cocaine does not affect the expression of 
these genes at the protein level. It is also possible that technical difficulties, including the 
lack of a positive control and the lack of quality controlled antibodies, may have 
contributed to the lack of useful data in this assay. For a sample Western blot for BNP, 
see Figure 5. 
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Figure 5. Representative example of Western blot for BNP (36 kDa) after 1X10" M 
cocaine treatment for 24 h. Colorimetric molecular weight markers in lane 1 
superimposed upon chemiluminescent reactions in remainder of membrane. 
Lane 2 = empty. Lanes 3, 5, and 7 = 0 M cocaine. Lanes 4, 6, and 8=1X10"2 M cocaine. 
Bracketed lanes are paired to each other. V = 0 M cocaine treated (cells 
treated with media only). C = 1X10" M cocaine treated. Unknown bands with 
strong immunoreactivity present near 160 kDa marker. 
Heart Function 
The purpose of these experiments was to characterize the functional response of 
the intact heart to acute cocaine exposure in vivo. The New Zealand White (NZW) rabbit 
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{Oryctolagus cuniculus) was used for these studies. Rabbits have been used extensively 
in studies designed to assess the impact of illicit drugs on the heart.133"135 The functional 
and anatomical features of the heart from this species are very similar to other mammals, 
including humans, making it ideal for our studies. 
With the animal under a surgical plane of anesthesia, cocaine was given as an 
intravenous bolus (2 mg/kg) and left ventricular function assessed. Acute exposure to 
cocaine significantly decreased heart rate at 15 min; dP/dt at 1 min; and -dP/dt at 5, 15, 
and 30 min relative to baseline control. The decrease in -dP/dt (lusitropy) was the only 
parameter sustained until the end of the experiment. Lusitropy is the rate of relaxation 
and is normally increased in response to sympathetic stimulation to allow for efficient 
ventricular filling of blood between contractions. A decrease in lusitropy is abnormal for 
a drug that is supposed to act as a sympathomimetic. In addition, cocaine significantly 
increased DREL at 15 min, however this was not sustained. These results suggest that in 
the intact rabbit, cocaine depresses overall cardiac function. This may be related to the 
ability of cocaine to increase ROS which may disrupt mitochondrial function and ATP 
production. Less ATP means less energy available to power myocardial contraction. 
With the exception of-dP/dt, all other functional parameters that were 
significantly altered by cocaine (HR, dP/dt, and DREL) returned to baseline before 
30 min. This may be due to the diminishing concentration of cocaine over time due to 
enzymatic metabolism and urinary elimination. The estimated half-life of cocaine 
(45 - 90 min) is very close to the end of the experimental time point. Table 13 
summarizes left ventricular functional findings in the rabbit acutely exposed to 2 mg/kg 
cocaine. 
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TABLE 13. Left Ventricular Function in NZW Rabbits Acutely Given 
Cocaine (2 mg/kg) 
Time HR MaxP EDP dP/dt -dP/dt 
(beats/min) (mm Hg) (mm Hg) (mm Hg/s) (mm Hg/s) 
Before Cocaine 218 ±20 70 ± 1 56 ± 2 1154+ 108 689+108 
lmin 206 + 28 66 + 4 52 + 6 923 + 173* 637+143 
After Cocaine 
5min 215 + 22 72 + 4 60 + 4 1106+178 644+120* 
After Cocaine 
15min 208 + 22* 71+4 57 + 3 1121+200 645+122* 
After Cocaine 
30min 213 + 28 71+6 58 + 5 1126+165 618+106* 
After Cocaine 
Data are stated as mean ± SD. (n = 4). HR = heart rate in beats/min. 
MaxP = maximum systolic pressure in mm Hg. EDP = end diastolic pressure in mm Hg. 
dP/dt = maximum rate of positive change in pressure (inotropy) in mm Hg/s. 
-dP/dt = maximum rate of negative change in pressure (lusitropy) in mm Hg/s. 
* = p < 0.05 vs. Before Cocaine. 
EXPERIMENTS WITH ECSTASY 
Dual-Luciferase Luminometry 
NF-KB activity is important to many myocardial pathophysiological processes 
including inflammation and hypertrophy. The purpose of these experiments was to 
observe the effects of ecstasy on the NF-KB response in cultured cardiac myocytes. 
We observed that 1X10"3 M and 1X10"2 M MDMA at 24 h significantly activated NF-KB 
in cultured H9c2 cells (Figure 6). IKB overexpression was able to significantly reduce 
the MDMA induced NF-KB response in the IKB + 1X10"3 M group, but not the IKB + 
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1X10" M group (Figure 7). These results indicate that in cultured cardiac myocytes, 
MDMA activates NF-KB in a dose-dependent manner and that IkB overexpression is 
sufficient to block this response at 1X10"3 M MDMA, but not at the high dose of 
1X10"2MMDMA. 
Figure 6. NF-KB activity in H9c2 cells stimulated with ecstasy for 24 h. (n = 3 separate 
experiments). Cells in the 0 M wells were exposed to media only and served as controls. 
Data are stated as mean RLU ratio ± SD. * = p < 0.05 vs. 0 M. 
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Figure 7. NF-KB activity in H9c2 cells co-transfected with NF-KB reporter and 
IKB overexpression vector and stimulated with ecstasy for 24 h. (n = 3 separate 
experiments). Cells in the 0 M + IKB wells were exposed to IKB overexpression 
vector in media only and served as controls. Data are stated as mean RLU ratio ± SD. 
* = p < 0.05 vs. 0 M + IKB. 
Reactive Oxygen Species 
ROS can damage biological macromolecules and cellular structure. ROS are also 
known to activate NF-KB. The purpose of these experiments was to observe the effects 
of ecstasy on ROS generation in cultured cardiac myocytes. H9c2 cells exposed to 
1X10"4 M or 1X10"3 M MDMA did not significantly affect ROS generation at any of the 
time points tested. However, exposure to 1X10" M MDMA caused a significant increase 
in ROS after 5 min (Table 14). This indicates that in cultured cardiac myocytes, a 
relatively high concentration of MDMA is required to induce significant ROS generation 
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above background. However, it is unknown if the lower concentrations may increase 
ROS generation at later time points (ie. beyond 5 min). 
TABLE 14. Mean Intensity of H9c2 Cells Loaded With 2',7'-Dichlorofluorescin 
Diacetate (ROS) Indicator and Stimulated With Ecstasy 
Drug 
Concentration 
1X10"4M 
1X10"3 M 
1X10"2M 
Control Signal 
547.1 ± 102.5 
595.8 + 55.3 
654.1 ±75.7 
ROS Signal 
2 min post-
ecstasy 
573.5 ±109.8 
611.7 ±50.2 
717.6 ±83.6 
ROS Signal 
5 min post-
ecstasy 
595.5 ±110.8 
660.6 ± 68.8 
782.1 ±80.4* 
* = p < 0.05 vs. Control Signal, (n = 3). 
Intracellular Calcium Experiments 
In cardiac myocytes, intracellular Ca2+ is an important ion involved with second 
messenger signaling and the excitation-contraction mechanism. Ca overload has been 
linked to myocardial apoptosis, hypertrophy, and dysfunction. The purpose of these 
experiments was to observe the effects of ecstasy on intracellular Ca2+ levels in cultured 
cardiac myocytes. H9c2 cells exposed to 1X10"4 M MDMA did not show a significant 
increase in intracellular Ca2+. However, exposure to 1X10"3 M and 1X10"2 M MDMA 
significantly increased intracellular Ca2+ at both the 2 and 5 min time points (Table 15). 
These results indicate that in cultured cardiac myocytes, MDMA can significantly 
elevate intracellular Ca +. In addition, since MDMA elevates intracellular Ca + at 
concentrations less than what is required for significant ROS generation, ROS may not 
play a role in Ca release from internal stores. 
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TABLE 15. Mean Intensity of H9c2 Cells Loaded With the Intracellular Ca 
Indicator Fluo-3 and Stimulated With Ecstasy 
Drug 
Concentration 
1X10"4M 
1X10"3 M 
1X10"2M 
Control Signal 
299.1 ±96.6 
207.1 ±118.7 
139.1 ±62.3 
Ca2+ Signal 
2 min post-
ecstasy 
284.2 ±96.1 
247.3 ±121.2* 
301.3 ±205.9* 
Ca2+ Signal 
5 min post-
ecstasy 
311.9+ 115.0 
254.0 ±145.0* 
320.9 ± 287.9* 
* = p < 0.05 vs. Control Signal, (n = 3). 
Gene Array 
The luminometry and confocal experiments revealed that ecstasy, at certain 
concentrations, can significantly activate NF-KB and elevate intracellular Ca in 
cultured cardiac myocytes. This could potentially alter the transcription of genes that are 
detrimental to cardiac homeostasis. Therefore, the purpose of these experiments was to 
characterize the genetic response of ecstasy treated H9c2 cells using arrays containing 
genes associated with cardiovascular disease and toxicity. 
Cultured H9c2 cells treated with 1X10"3 M ecstasy for 24 h exhibited alterations in 
mRNA expression levels of some genes on each array (Tables 16 and 17). Ecstasy 
upregulated genes associated with inflammation, hypertrophy, and coronary heart 
disease (Table 16). Upregulation of the Tnni3 gene was verified by temperature gradient 
RT-PCR (Figure 8). Increased expression of this gene is associated with myocardial 
hypertrophy. These results indicate that the detrimental effects of ecstasy extend to the 
genetic level. However, ecstasy also upregulated DNA repair, stress response, and pro-
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survival genes while simultaneously downregulating pro-apoptotic genes (Table 17), 
showing that, like cocaine, a compensatory response may be activated by this drug. 
TABLE 16. Genes Affected by Ecstasy in H9c2 Cells: Mouse Cardiovascular 
Disease Biomarkers Array 
Additional Information Gene Signal Ratio 
Gene associated with Apoc2 (Apolipoprotein C-II) 7.12 
coronary heart disease 
Genes associated with MCP-1 (monocyte 8.47 
inflammation chemoattractant protein 1) 
VCAM-1 (vascular cell 12.13 
adhesion molecule 1) 
Gelatinase A 0.05 
PLAUR (plasminogen 7.70 
activator urokinase receptor) 
Timp (matrix 0.41 
metalloproteinase inhibitor) 
Gene associated with Tnni3 (troponin I type 3) 6.12 
cardiac hypertrophy 
Genes from the Mouse Cardiovascular Disease Biomarkers array. 
Signal ratio = [(target geneexp-blankexp)/(GAPDHexp-blankeXp)]/[(target genecontroi-
blankControi)/(GAPDHControi-blankCOntroi)]- » 1 0 = a large positive response with a low 
control signal. 
Genes associated with 
cardiac remodeling 
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TABLE 17. Genes Affected by Ecstasy in H9c2 Cells: Mouse Stress & 
Toxicity Pathway Finder Array 
Additional Information Gene Signal Ratio 
Genes associated with caspase-1 0.41 
apoptosis caspase-8 0.13 
FasL 0.23 
p53 0.33 
cyclinDl 3.25 
cyclin G 6.77 
PCNA (proliferating cell 8.89 
nuclear antigen) 
cryab (alpha B-crystallin) 2.07 
hsp2 5 (heat shock protein 25) 3.55 
hsp60 (heat shock protein 60) 2.87 
hspa4 (heat shock protein a4) 4.27 
hspa9 (heat shock protein a9) 2.43 
Genes associated with Gadd45 2.41 
DNA repair RAD23A 5.27 
Genes associated with Cox-2 (cyclooxygenase-2) 4.29 
inflammation MIP-lb (macrophage 2.13 
inflammatory protein-1 beta) 
Genes from the Mouse Stress & Toxicity Pathway Finder array. 
Signal ratio = [(target geneexp-blankeXp)/(GAPDHexp-blankexp)]/[(target genecontroi-
blankCOntroi)/(GAPDHControi-blankCOntroi)]- » 1 0 = a large positive response with a low 
control signal. 
Genes associated with 
cardiac hypertrophy 
Genes associated with 
stress response and 
pro-survival 
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Figure 8. Temperature gradient RT-PCR for Tnni3 gene H9c2 cells. Lane 4 optimal 
annealing temperature 59.1°C. Tnni3 gene was normalized to GAPDH (housekeeping 
gene) signal. Semi-quantitative densitometry analysis indicated that Tnni3 mRNA was 
increased in the MDMA group compared to the placebo group. Left = placebo. Right = 
MDMA. 
Immunohistochemistry 
The gene array experiments in which H9c2 cells were exposed to ecstasy indicated 
that the mRNA transcript levels of certain genes are affected by ecstasy. Therefore, the 
purpose of these experiments was to measure the protein level expression of array-
specific genes in ecstasy treated heart tissues from our functional experiments. The 
expression of Tnni3 was analyzed in these experiments. This gene is known to be 
upregulated during cardiac hypertrophy. The expression of BNP and CRP were also 
analyzed. Both BNP and CRP are upregulated during heart failure. Although the 
antibody specific stain for Tnni3 revealed the presence of this protein in both placebo 
and MDMA treated heart tissues, densitometry analysis of rabbit myocardium acutely 
exposed to 2 mg/kg MDMA for 15 min did not reveal any significant difference in the 
amount of Tnni3 expression compared to placebo. In addition, no significant differences 
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were found in the other proteins analyzed (BNP and CRP). These data suggests that 
MDMA does not affect the expression of these genes at the protein level and may be due 
to the short duration of exposure to drug given as an intravenous bolus (15 min). 
Western Blot 
The gene array experiments indicated that the mRNA transcript levels of certain 
genes are affected by ecstasy. Therefore, the purpose of these experiments was to 
measure the protein level expression of array-specific genes in ecstasy treated cardiac 
myocytes. VCAM-1 and iNOS are known to be upregulated during myocardial 
inflammation. VCAM-1 was also upregulated in our array experiments. Although iNOS 
was not upregulated on the array, we nevertheless decided to test for the expression of 
this protein because it is known to be NF-KB dependent. We performed Western blot 
analysis for these proteins in cultured H9c2 cells exposed to either 2 uM or 1 mM 
ecstasy for 3, 6, or 12 h. These concentrations and time points were chosen because they 
corresponded with the same concentrations and time points of significant NF-KB activity 
in our ELISA experiments. 
We saw no significant difference in VCAM-1 or iNOS expression compared to 
0 M control. Immunoreactive bands either did not resolve near the appropriate molecular 
weight markers, or did not resolve at all for either protein. These results suggest that 
ecstasy does not affect the expression of these genes at the protein level. However, it is 
possible that these time points are too early for a significant amount of detectable protein 
expression to occur. It is also possible that technical difficulties, including the lack of a 
positive control and the lack of quality controlled antibodies, may have contributed to 
the lack of useful data in this assay. For a sample Western blot for iNOS, see Figure 9. 
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Figure 9. Representative example of Western blot for iNOS (130 kDa) after 1 mM 
ecstasy treatment for 6 h. Colorimetric molecular weight markers in lane 1 superimposed 
upon chemiluminescent reactions in remainder of membrane. 
< = iNOS positive control in lane 8. Lanes 2, 4, and 6 = 0 M ecstasy. Lanes 3, 5, 
and 7 = 1 mM ecstasy. Bracketed lanes are paired to each other. V = 0 M ecstasy 
treated (media only). E = 1 mM ecstasy treated. 
ELISA 
Our luminometry assay revealed that ecstasy activates NF-KB in cultured cardiac 
myocytes after 24 h of exposure. Since it was possible that ecstasy may activate NF-KB 
at earlier time points, we performed a series of experiments to test drug exposure 
durations of 3, 6, and 12 h. Enzyme-linked immunosorbent assay (ELISA) provides an 
alternative and rapid method for detecting NF-KB activity in ecstasy treated cardiac 
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myocytes. We tested 2 [iM MDMA because this concentration is close to that in the 
plasma of actual users of this drug. We tested 1 mM MDMA because this concentration 
was the minimum capable of activating NF-KB in our luminometry experiments. We 
tested 10 mM MDMA because this was the highest concentration capable of activating 
NF-KB in our luminometry experiments. 
We observed significant NF-KB p50 activity in H9c2 cells exposed to 2 uM 
MDMA at the 12 h time point and 1 mM MDMA at the 6 h time point (Figures 10 and 
11). However, we did not observe significant NF-KB p50 activity in H9c2 cells exposed 
to 10 mM MDMA for any of the time points tested (Figure 12). These findings, with the 
exception of the 10 mM MDMA group, indicate that MDMA activates NF-KB in 
cultured cardiac myocytes at time points significantly less than 24 h. 
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Figure 10. ELISA for NF-KB p50 activity in H9c2 cells stimulated with 2 uM 
ecstasy for 3, 6, or 12 h. (n = 3 separate experiments). Cells in the 0 uM wells were 
exposed to media only and served as controls. Data are stated as mean A450 ± SD. 
* = p < 0.05 vs. 0 \M. 
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Figure 11. ELISA for NF-KB p50 activity in H9c2 cells stimulated with 1 mM 
ecstasy for 3, 6, or 12 h. (n = 3 separate experiments). Cells in the 0 mM wells were 
exposed to media only and served as controls. Data are stated as mean A450 ± SD. 
* = p < 0.05 vs. 0 mM. 
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Figure 12. ELISA for NF-KB p50 activity in H9c2 cells stimulated with 10 mM 
ecstasy for 3, 6, or 12 h. (n = 3 separate experiments). Cells in the 0 mM wells were 
exposed to media only and served as controls. Data are stated as mean A450 ± SD. 
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Since it remained possible that ecstasy could activate NF-KB at time points earlier 
than 3 h, we performed another series of experiments involving drug exposure durations 
of 15, 30, and 60 min. We did not observe significant NF-KB p65 activity in H9c2 cells 
exposed to 2 uM or 1 mM MDMA at either the 15, 30, or 60 min time points (Figure 
13). Similarly, we did not observe significant NF-KB p50 activity in rabbit myocardium 
acutely exposed to MDMA from our functional experiments (Figure 14). These results 
suggest that these time points of exposure may be too early for significant nuclear 
accumulation of NF-KB. 
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Figure 13. ELISA for NF-KB p65 activity in H9c2 cells stimulated with 2 uM or 1 mM 
ecstasy for 15, 30, or 60 min. (n = 3 separate experiments). Cells in the 0 uM wells were 
exposed to media only and served as controls. Data are stated as mean A450 ± SD. 
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Figure 14. ELISA for NF-KB p50 activity in rabbit myocardium stimulated with 
2 mg/kg ecstasy for 15 min. (n = 3 separate experiments). Placebo animals were exposed 
to 0.9% saline only and served as controls. Data are stated as mean 
A450 + SD. 
Heart Function 
The purpose of these experiments was to characterize the functional response of 
the intact heart to acute ecstasy exposure. The same animal model and measuring 
techniques were used as in our cocaine experiments. Acute exposure to ecstasy 
significantly increased heart rate at all time points, EDP at 5 min, and MinP at 5 min 
relative to baseline control. After an initial drop at 1 min, ecstasy also significantly 
increased dP/dt at 5 min. Ecstasy significantly decreased -dP/dt at 1 min and DREL at 5 
and 15 min. These results suggest that in the intact rabbit, ecstasy acutely increases 
cardiac stress by increasing heart rate and contractility. The early decrease in lusitropy 
prevents the heart from efficiently relaxing between contractions which reduces 
efficiency of ventricular chamber filling between contractions. However, this effect was 
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short-lived and followed by an increase in dP/dt which suggests a compensatory increase 
in contractility to counteract the reduced cardiac output cause by inefficient chamber 
filling. The elevation of EDP at the same time period of 1) increased dP/dt and 2) lack of 
significant increase in MaxP, suggests a type of diastolic failure where EDP remains 
elevated not because of increased blood volume loading, but because of decreased ability 
to fully relax. Table 18 summarizes the left ventricular functional findings in the rabbit 
acutely exposed to 2 mg/kg ecstasy. 
TABLE 18. Left Ventricular Function in NZW Rabbits Acutely Given 
Ecstasy (2 mg/kg) 
Time HR MaxP EDP dP/dt -dP/dt 
(beats/min) (mm Hg) (mm Hg) (mm Hg/s) (mm Hg/s) 
Before MDMA 191 ± 12 31 ±3 24 ±2 503 ± 88 276 ±61 
lmin 218 ±22* 32 ± 8 26 ± 9 363 ± 105* 227 ± 72* 
After MDMA 
5min 226 ±23* 40 ±13 33 ±11* 570 ±91* 290 ±83 
After MDMA 
15min 222 + 30* 36 ±11 28 ± 9 591 ±99 280 ±57 
After MDMA 
Data are stated as mean ± SD. (n = 7). HR = heart rate in beats/min. 
MaxP = maximum systolic pressure in mm Hg. EDP = end diastolic pressure in mm Hg. 
dP/dt = maximum rate of positive change in pressure (inotropy) in mm Hg/s. 
-dP/dt = maximum rate of negative change in pressure (lusitropy) in mm Hg/s. 
* = p < 0.05 vs. Before MDMA. 
Atherosclerosis is a widespread disease condition of fatty substance accumulation, 
inflammation, and remodeling of the vascular wall. During atherosclerosis, the 
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endothelium is lesioned and this causes a decrease in nitric oxide synthase (NOS) 
activity. NOS generated nitric oxide (NO) is known to have beneficial effects on 
cardiovascular function including anti-platelet adhesion, vasodilation, and reduction of 
myocardial inotropy. It is not uncommon for people with this condition to use illicit 
drugs including ecstasy. Therefore, in a related set of functional experiments, the ability 
of ecstasy to alter heart function in the presence of NOS inhibition was measured. A 
baseline functional reading was recorded for 10 min prior to the delivery of any 
substance. Then, the NOS inhibitor L-NAME was injected intravenously and another 
functional baseline was recorded for 10 min. Finally, MDMA was injected intravenously 
and left ventricular function analyzed. 
We observed that pre-treatment with L-NAME alone significantly decreased heart 
rate, but significantly elevated MaxP, EDP, MinP, 1/2R, and DREL (Figures 15 and 16). 
MDMA exposure after L-NAME pre-treatment significantly decreased heart rate at 1 
and 5 min, but significantly elevated MaxP, EDP, and MinP at all time points. DREL 
was also significantly elevated at 15 min. See table 19 for a summary of our findings. 
MDMA exposure after L-NAME pre-treatment significantly increased DCON at the 1 
min mark, an aberration that was not caused by MDMA alone or L-NAME pre-treatment 
alone. In addition, the abnormalities in EDP and MinP caused by MDMA alone or L-
NAME alone were exacerbated by the combination of the two substance. These findings 
suggest that L-NAME and MDMA are synergistically detrimental to heart function. 
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Figure 15. Effects of L-NAME pre-treatment alone on left ventricular function in NZW 
rabbits: HR, dP/dt, -dP/dt, Vi R, DREL. (n = 4 separate experiments). HR = heart rate in 
beats per min. dP/dt = maximum rate of positive change in pressure (inotropy) in mm 
Hg/s. -dP/dt = maximum rate of negative change in pressure (lusitropy) in mm Hg/s. 
1/2R = duration of one-half relaxation in ms. DREL = duration of relaxation in ms. Data 
are stated as mean ± SD. * = p < 0.05. 
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Figure 16. Effects of L-NAME pre-treatment alone on left ventricular function in NZW 
rabbits: MaxP, EDP, MinP, DCON. (n = 4 separate experiments). MaxP = maximum 
systolic pressure in mm Hg. EDP = end diastolic pressure in mm Hg. MinP = minimum 
diastolic pressure in mm Hg. DCON = duration of contraction in ms. Data are stated as 
mean±SD. * = p < 0 . 0 5 . 
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TABLE 19. Left Ventricular Function in NZW Rabbits Pre-Treated With 
L-NAME (10 mg/kg) for 10 min and Acutely Given Ecstasy (2 mg/kg) 
Time HR MaxP EDP dP/dt -dP/dt 
(beats/min) (mm Hg) (mm Hg) (mm Hg/s) (mm Hg/s) 
Before L-NAME 173 + 14 21 ±4 14 ±3 442+110 217185 
L-NAME INJECTION 
10 min 104+10* 27 ± 5 * 19 ± 3 * 408 ± 143 121 ± 8 
After L-NAME 
MDMA INJECTION 
lmin 118 ±13* 51 ±4* 33 ± 3 * 459 ± 94 174 ±19 
After MDMA 
5 min 138 ±18 39 ± 3* 28 ±3* 499 ±154 159 ±29 
After MDMA 
15 min 122 ±14* 32 ± 3 * 23 ±2* 466+149 142 ±29 
After MDMA 
Data are stated as mean ± SD. (n = 4). HR = heart rate in beats/min. 
MaxP = maximum systolic pressure in mm Hg. EDP = end diastolic pressure in mm Hg. 
dP/dt = maximum rate of positive change in pressure (inotropy) in mm Hg/s. 
-dP/dt = maximum rate of negative change in pressure (lusitropy) in mm Hg/s. 
* = p < 0.05 vs. Before L-NAME. 
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DISCUSSION AND CONCLUSION 
Cocaine and MDMA are among the most commonly used illicit drugs and their 
effects on the heart have not been fully characterized. The current study involved several 
independently performed experiments designed to expand our understanding about how 
these drugs affect the heart at a cellular and intact organ system level. The present results 
indicate that cocaine and MDMA are detrimental to multiple parameters of myocardial 
homeostasis and that some pre-treatment strategies may have significant prophylactic 
potential. 
NF-KB is a critical transcription factor at the center of the inflammatory and 
hypertrophic response of the heart. Cocaine and MDMA activated NF-KB in a dose-
dependent manner. To the best of our knowledge, this is the first time that either cocaine 
or MDMA has been shown to activate NF-KB in cultured cardiac myocytes. This finding 
helps to explain some of the observations made by previous investigators, whereby the 
administration of cocaine or MDMA significantly enhanced leukocyte infiltration into 
the myocardium.59'63'67 Activation of NF-KB by these drugs provides a mechanism by 
which this inflammatory response may happen. 
Since MDMA activated NF-KB at 24 h, we decided to explore the possibility of 
MDMA-induced NF-KB activation at time points of exposure considerably less than 
24 h. Using an ELISA protocol, we found that 1.0 mM MDMA significantly activated 
NF-KB in cultured cardiac myocytes at 6 h. This concentration was the minimal amount 
capable of activating NF-KB. At 12 h, 2.0 uM MDMA significantly activated NF-KB. 
This concentration is within the range of peak plasma levels seen in actual users of this 
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drug. It is interesting that NF-KB was not activated at or before 3 h with either 
concentration. It is possible that under the current experimental conditions this amount 
of time is not sufficient for significant nuclear accumulation of this transcription factor. 
It is also possible that a significant amount of NF-KB activity could be occurring within 
the time period just before our earliest assay point (15 min). 
A biphasic response to 1.0 mM MDMA is suggested since sometime after 6 h, 
NF-KB activity becomes significantly degraded (no significant activity at 12 h), but then 
reappears at 24 h according to our luminometry experiments. It is uncertain why MDMA 
is associated with such a temporal response with regard to NF-KB. It is possible that 
some metabolic by-product of MDMA may be participating later in the NF-KB response 
and/or cellular adaptation is occurring in response to the persistent presence of the drug 
and its metabolites over time. 
We also tested 10 mM MDMA, the only other concentration that significantly 
activated N F - K B . We expected a strong and early activation of NF-KB at this high 
concentration. However, we did not observe a significant response at any of the time 
points tested. It is unclear why this result occurred. One possibility may be issues 
regarding the sensitivities of the different assays. If luminometry is more sensitive than 
ELISA, as it has been suggested, then perhaps the latter assay may not be able to resolve 
a very slight difference between treatment groups even though one may exist. In order to 
confirm this theory, additional experiments with MDMA at the same concentrations and 
exposure time points would have to be performed and then analyzed using luminometry. 
Another possibility involves alternative NF-KB dimers. There are 15 possible dimer 
combinations that can be made from p50, p52, p65, cRel, and RelB proteins. Of these, 
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9 are known to have transcriptional activity.136 One theory states that the cellular 
repertoire of NF-KB dimers can be altered in response to certain stimuli. If this 
repertoire should change in response to very high concentrations of ecstasy, then one set 
of NF-KB dimers containing p50 may be involved with the ELISA signaling seen with 
2 uM MDMA and 1 mM MDMA, while another set of NF-KB dimers without p50 may 
be involved with the luminometry signaling seen with 10 mM MDMA. This would help 
explain the lack of p50 signaling in the ELISA assay at this high concentration. 
Both cocaine and MDMA have been shown to reduce the amount of intracellular 
glutathione, a major antioxidant. Therefore, it is possible that exposure to either of these 
drugs may cause perturbations in redox balance, which may lead to a net increase in 
reactive oxygen species (ROS) generation. These free-radicals are known for their direct 
deleterious effects on the heart, and also as activators of myocardial NF-KB. In order to 
explore the possibility of ROS involvement in the cocaine and MDMA induced 
activation of N F - K B , fluorescence based confocal microscopy was used to measure the 
relative amounts of ROS generated in cultured cardiac myocytes after exposure to each 
drug. Within a few minutes, both drugs caused a significant increase in the appearance 
of ROS above background. For MDMA, the minimal concentration and time required to 
induce this response was 1X10" M at 5 min, and for cocaine, a minimum of 1X10" M at 
2 min was required. These findings suggest that under our experimental conditions, 
cocaine is more potent than MDMA in generating ROS and that these free radicals may 
be responsible for the ability of these drugs to activate NF-KB. 
Since a significant amount of ROS was generated upon exposure to cocaine, and 
ROS are known to activate NF-KB, we were interested in observing the effects of 
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antioxidant pre-treatment on cocaine induced ROS generation and NF-KB activity in 
cultured cardiac myocytes. In addition, because cocaine induced catecholaminergic 
stimulation is known to elevate both intracellular Ca2+ and ROS, we also tested the 
efficacy of Ca channel blocking and P-adrenergic receptor blocking pre-treatment to 
reduce cocaine induced ROS. 
We found that pre-treatment with 1 mM N-acetyl-L-cysteine (NAC) or 10 uM 
nifedipine significantly reduced the amount ROS normally generated by 1X10" M 
cocaine. However, this effect was not sustained by nifedipine. In addition, pre-treatment 
with 1 mM NAC or the combination of 1 mM NAC + 1 mM glutathione significantly 
'y 
suppressed the NF-KB reporter activity normally induced by 1X10" M cocaine. Pre-
treatment with 1 mM glutathione also tended to suppress NF-KB reporter activity, 
however, the data for this group did not reach statistical significance. Apparently, the 
extra free radical buffering capacity offered by antioxidant (1 mM NAC) pre-treatment 
was sufficient in quenching enough of the ROS generated by cocaine to attenuate the 
NF-KB response. These observations support the assertion that cocaine induced ROS 
generation is responsible for the ability of this drug to activate NF-KB in cultured cardiac 
myocytes. 
Ca2+ is an important ion that acts as both as a second-messenger and as a direct 
effector in the excitation-contraction mechanism of the heart. We found that cocaine and 
MDMA could significantly increase intracellular Ca in cultured cardiac myocytes. For 
MDMA, the minimal concentration and time required to induce this response was 
1X10"3 M at 2 min, and for cocaine, a minimum of 1X10"4 M at 2 min was sufficient. 
Again, these findings suggest that under our experimental conditions, cocaine is more 
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potent than MDMA in elevating intracellular Ca2+ and that these drugs may alter 
intracellular signaling, gene expression, and myocardial rhythmicity and contractility 
due to the important role of Ca2+ in these processes. 
9+ 
Since intracellular Ca was significantly elevated upon exposure to cocaine, we 
9+ 
were interested in observing the effects of antioxidant and Ca channel blocking pre-
9+ 
treatment on cocaine induced intracellular Ca elevation in cultured cardiac myocytes. 
Pre-treatment with 1 mM NAC significantly attenuated the intracellular Ca2+ elevation 
normally induced by 1X10"4 M and 1X10"3 M cocaine, but not by 1X10"2M cocaine. We 
also found that pre-treatment with either 10 uM verapamil or 10 uM nifedipine 
significantly attenuated the intracellular Ca2+ elevation normally induced by 1X10"4 M 
9+ 
cocaine. Verapamil also significantly attenuated the intracellular Ca elevation normally 
induced by 1X10"3M cocaine, although this effect was short-lived. 
It is evident that Ca channel blockers offer significant but limited protection 
against intracellular Ca2+ overload induced by cocaine. This finding suggests that 
cocaine may mediate some of its effects via altering intracellular Ca2+ signaling and that 
the extracellular space is at least one source of this extra Ca2+. Since free-radical 
9+ 
quenching appears to be more effective at higher concentrations of cocaine than Ca 
blockade alone, the other source must come from some internal store that sequesters 
9-1-
Ca from being free in the cytosol, such as the mitochondria or the sarcoplasmic 
reticulum. Because of the destructive nature of free-radicals on biological 
macromolecules, it may be possible to physically compromise these membrane bound 
internal reservoirs in the absence of sufficient antioxidant protection and cause leakage 
of free Ca2+ into the cytosol. The protective property of NAC to help guard against 
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abnormal intracellular Ca elevation has been recently described in lung epithelial 
cells.137 
Since NF-KB was activated by certain concentrations of cocaine, and NF-KB 
activity enhances the transcription of certain genes, we decided to study the effects of 
this drug on modulating genes associated with cardiovascular disease and toxicity. To 
determine the effects of cocaine on gene expression profiles, we analyzed gene arrays 
with probes made from total mRNA isolated from cocaine treated cultured cardiac 
myocytes and rabbit ventricular myocardium. A number of genes associated with 
cardiovascular disease were activated by cocaine. It was not feasible to verify the 
activation of all genes with a signal ratio of 2.0 or above, therefore only a few genes on 
each array were confirmed via RT-PCR. Of particular interest were the genes associated 
with ischemia, remodeling, and heart failure, including atrial natriuretic peptide (ANP), 
C-reactive protein (CRP), and brain natriuretic peptide (BNP).138"140 Elevated TNFa, an 
NF-KB dependent cytokine, has been linked to apoptosis, inflammation, hypertrophy, 
and heart failure.55 The increased transcription of peroxisome proliferator activated 
receptor-gamma (PPARy) may be compensatory in response to the oxidative stress 
induced by cocaine.141 Activation of the KCNA5 gene could instigate some of the 
cardiac arrhythmias seen in chronic cocaine users, due to the important role of voltage-
gated potassium channels during the repolarization phase of the cardiac action 
potential.142 The rapidity of the response in the rabbit heart, with significant increases in 
expression within 30 min is not unheard of in other systems.143'144 Increases in Ca2+ and 
mitochondrial depolarization are known to be capable of instigating these changes 
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during ischemia and heart failure, therefore similar increases caused by cocaine exposure 
may also have that potential. 
Cocaine mediated activation of many of these genes are consistent with the 
clinical profile reported by Missouris et al. and suggests that cocaine may set into motion 
transcriptional activity that, if maintained sufficiently, could predispose the individual to 
chronic cardiovascular dysfunction.145 Activation of genes in our acute preparations 
could contribute to cocaine-induced cardiac toxicity if these changes in gene 
transcription are maintained and manifested as changes in cardiac protein expression. 
For example, several gene products that could be traced to hypertrophy include increases 
in both the [3-adrenergic receptor and angiotensinogen genes. The latter was of specific 
interest to us since we previously reported that cocaine increased plasma renin activity 
(PRA).18 Angiotensinogen is a precursor for the production of angiotensin II, a strong 
vasoconstrictor known to lead to hypertension and cardiac hypertrophy.146'147 
Genetic microarry was also used to determine if MDMA could alter gene 
transcription profiles in cultured cardiac myocytes. MDMA increased the transcription 
of the Cox-2 gene. This gene encodes for an enzyme known to be localized within 
regions of myocardial inflammation and fibrotic scar formation, especially in patients 
with congestive heart failure. The upregulation of the MCP-1 and MlP-lb genes 
suggests that these chemotactic proteins may promote leukocyte migration to the 
myocardium.148,149 The adhesion molecule gene VCAM-1 was strongly upregulated, 
displaying a 12-fold increase over control. VCAM-1 may be involved with leukocyte 
binding and infiltration into the myocardium.110 This particular gene is specifically 
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regulated by N F - K B , corroborating the increased activity of NF-KB observed in our 
genetic reporter studies. 
The activity of two genes associated with myocardial remodeling and hypertrophy 
were also affected by MDMA. Gelatinase A, which encodes for a matrix degrading 
enzyme, and its inhibitor Timp were downregulated.150 This suggests that MDMA may 
not alter the extracellular matrix. However, the increased transcription of growth 
promoting genes such as cyclin Dl, cyclin G, and PCNA suggests that MDMA may be 
pro-hypertrophic.151"154 The ability of MDMA to activate growth related genes may act 
in synergy with its systemic ability to enhance the release of norepinephrine, another 
stimulator of hypertrophic growth in the chronically affected myocardium.117 
Several other key genes were activated in the presence of MDMA including heat-
shock proteins aB-crystallin (cryab), mortalin-2 (PBP74), HSP25, and HSP60. These 
pro-survival genes are normally induced by chemical, hyperosmotic, and ischemic 
insults.155"158 In addition, the upregulation of DNA-repair factors Gadd45 and RAD23A 
suggests that MDMA may also have genotoxic properties.159'160 The activation of these 
genes by MDMA suggests that the cells are stressed by the drug and that a compensatory 
response is initiated to counteract exposure and promote survival. Furthermore, MDMA 
appeared to downregulate the pro-apoptotic genes caspase-1, caspase-8, FasL, and p53 
suggesting that under our experimental conditions, the adverse effects associated with 
MDMA may not be caused by activation of apoptosis.161"165 
Genetic arrays provide the advantage of observing the activity of several genes 
simultaneously at the level of transcription. However, changes in mRNA transcript 
levels may not be finally manifested as changes in protein expression that significantly 
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influence a particular pathology. One important limitation is that post-transcriptional 
events may also influence the ultimate expression of a gene in question and this cannot 
be determined with the present methodology. We therefore turned to antibody based 
methods such as immunohistochemistry and Western blotting in an attempt to measure 
the expression of select genes at the protein level. However, for both cocaine and 
MDMA, we were unable to observe any significant differences between treatment 
groups in either rabbit heart tissue or H9c2 cells. We are not certain why these assays did 
not reveal any useful information. It is possible that, at the protein level, the selected 
genes are simply not affected by our experimental treatments. Also, technical difficulties 
remain a possibility, even though in some instances a strong positive control signal was 
obtained. 
In our functional studies of the intact rabbit heart, cocaine caused the appearance 
of several acute abnormalities, including a significantly decreased heart rate, decreased 
inotropy, decreased lusitropy, and increased duration of relaxation. The cocaine 
mediated intracellular Ca elevation and increased ROS generation that we observed in 
cultured cardiac myocytes could help explain the impairment of ventricular relaxation 
and reduced heart rate. Other investigators have shown that cocaine increased oxidative 
stress in the myocardium of rats before cardiac dysfunction occurred and that the left 
ventricular dysfunction was prevented by antioxidants.166 Another likely contributor to 
the decline in heart rate and left ventricular inotropy could be the anesthetic property of 
cocaine and its ability to block sodium channel conductance, thereby slowing conduction 
velocity through the myocardium. In anesthetized animals, this property has been shown 
95 
to have an overriding effect on the otherwise positive inotropic actions normally 
attributed to cocaine.167 
MDMA also caused acute functional abnormalities of the left ventricle. Compared 
to placebo, MDMA alone caused significant increases in heart rate, end diastolic 
pressure, and minimum diastolic pressure. MDMA also caused significant decreases in 
lusitropy and duration of relaxation. Interestingly, the effect on inotropy was mixed with 
a significant decrease at the 1 min mark followed by a significant increase at the 5 min 
mark. Due to the early onset of these cardiovascular responses, and the fact that MDMA 
induced NF-KB activation in our cultured cardiac myocytes was not observed at or 
before the 3 h time point, these responses may not be the result of interaction with the 
myocardial NF-KB pathway. Two possibilities may explain these results. The injected 
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MDMA may have directly and rapidly affected Ca homeostasis in peripheral blood 
vessels and led to the slight increase in systolic and diastolic pressures. It is also possible 
that MDMA may have stimulated systemic sympathetic activity by causing a net 
increase in epinephrine and norepinephrine release from the adrenal medulla and 
peripheral nerve endings. This idea is supported by the fact that there was a rapid and 
significant increase in heart rate during all time periods tested after MDMA injection. 
MDMA caused significant intracellular Ca elevation in cultured H9c2 cells 
within a few minutes after administration. Elevated Ca2+ levels may affect intracellular 
signaling pathways leading to diverse pathological responses including fibrosis and 
hypertrophy. Disruptions in calcium homeostasis may also alter myocardial excitability 
and contractility, which may induce ventricular arrhythmia and other more immediate 
functional abnormalities such as those observed in the present study. An increase in 
heart rate along with a decrease in the duration of the cardiac cycle suggests that filling 
and ejection of blood in the heart exposed to MDMA may be acutely compromised. 
Although we exposed the H9c2 heart cells to MDMA acutely and measured ROS 
generation 5 min later, the half-life of MDMA has been reported to be approximately 
8 h.66 In addition, there is evidence that MDMA metabolites adversely affect cardiac 
myocyte redox balance.84 MDMA is metabolized into a variety of other compounds all 
of which may have biologic activity and thus may prolong the exposure of the 
myocardium to the deleterious effects of the drug such as ROS generation. In vivo and 
in vitro studies provide evidence supporting the role of oxidative stress in cardiovascular 
conditions (ex. ischemia-reperfusion injury, hypertension, and catecholamine-induced 
cardiomyopathy) that ultimately lead to cardiovascular dysfunction.168'169 
Significant NF-KB activity was absent in the myocardial tissue samples from our 
functional experiments. Since the animals were exposed to MDMA for 15 min prior to 
euthanasia, this lack of NF-KB activity is in agreement with our cell culture findings at 
the same time point. Therefore, it is unlikely that any functional abnormalities induced 
by acute MDMA exposure are due to the activation of NF-KB within the myocardium 
and the consequent expression of downstream dependent genes. However, it is possible 
that other tissues, such as the vasculature or sympathetic peripheral nerve endings may 
be responsive to this drug within the tested timeframe and may contribute to the 
abnormal functional findings in the left ventricle by increasing peripheral resistance or 
prolonging catecholaminergic stimulation of the heart. Another possibility that may 
explain the rapid effects of MDMA on ventricular function involves MDMA induced 
ROS generation and abnormal intracellular Ca2+ elevation. These events may present a 
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more immediate threat to normal heart function since they were precipitated quite 
rapidly in our cultured cardiac myocytes after drug exposure. 
Since MDMA activates NF-KB, we predicted that downstream dependent genes 
such as inducible nitric oxide synthase (iNOS) would be upregulated as a result of 
MDMA exposure. iNOS is a cardioprotective enzyme closely associated with 
compensatory actions in the heart during ischemic preconditioning and inflammatory 
cytokine exposure.170'171 It is possible that MDMA stresses the heart and causes the 
myocardium to respond in an adaptive manner by increasing the synthesis of this 
enzyme. In the current study, we performed an independent series of experiments in 
which we again exposed H9c2 heart cells in culture to 2.0 uM and 1.0 mM 
concentrations of MDMA. However, we did not observe a significant change in the 
expression of iNOS at the protein level. 
Regardless of the exact source of nitric oxide, the importance of an intact nitric 
oxide response system is readily apparent in our functional experiments. L-NAME is a 
well characterized non-specific inhibitor of the major NOS isoforms.172'173 In the rat, this 
compound induces a dose-dependent increase in heart rate and mean arterial pressure.172 
L-NAME also decreases blood flow by increasing vasoconstriction in several vascular 
beds including those associated with the kidneys, mesenteries, and hindquarters.174 
In our experiments, injection of L-NAME alone caused a significantly decreased 
heart rate, but increased left ventricular systolic and diastolic pressures, Vi relaxation, 
and duration of relaxation. In contrast, when MDMA was given alone, heart rate 
increased and the duration of relaxation decreased. These results are consistent with 
what was expected since the duration of the cardiac cycle is inversely proportional to the 
98 
heart rate. In the presence of L-NAME, MDMA decreased heart rate and increased the 
duration of the cardiac cycle. These results suggest that one mechanism used by MDMA 
to alter heart function is via the nitric oxide synthase pathway. Nitric oxide has been 
shown to play a role in the modulation of sympathetic nerve activity and baroreflex 
sensitivity.175 For instance, if MDMA and L-NAME are both sympathomimetic 
synergists, then the increased systolic pressure induced by L-NAME may be enhanced 
by the addition of MDMA. The consequent decrease in heart rate may be exclusively 
due to the effects of L-NAME or the compensatory baroreceptor reflexes of the intact 
cardiovascular system responding to the elevations in pressure. It is therefore not 
possible, in this model, to separate the reflex component of the response to these drugs. 
These findings have important implications for users of MDMA with a compromised 
vascular endothelium, as seen in the atherosclerotic vasculature. Endothelial cells are an 
important source of nitric oxide. Therefore, users of MDMA with extensive 
atherosclerotic lesions may be at increased risk for the development of acute heart 
failure. 
A myriad of pathophysiological events can be triggered by cocaine or MDMA 
administration. Many of these events, such as ischemia-reperfusion of the myocardium, 
prolonged catecholaminergic stimulation, and rhabdomyolysis of skeletal muscles, are 
well described and can induce ROS generation, intracellular Ca elevation, and 
myocardial dysfunction secondary to administration of the drugs themselves. On the 
other hand, information concerning the direct/primary effects of cocaine and MDMA on 
the myocardium is relatively scarce. Given the high potential for cocaine and ecstasy 
abuse, it is important to elucidate mechanisms of pathology in order to effectively 
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identify possible treatment strategies. The current study significantly adds to our 
understanding about the effects of cocaine and MDMA on the heart, however, full 
characterization of these drugs remains incomplete. 
Based on what we have observed, it would be prudent to perform additional 
experiments that will complement and extend our understanding about cocaine, MDMA, 
and any potential prophylactic agents. For example, although we were able to observe 
the beneficial effects of antioxidant pre-treatment in several of our experiments with 
cocaine, it remains to be seen if the same type of pre-treatment would be just as effective 
in the case of MDMA. Moreover, since the gold-standard in any efficacy study involving 
the heart is the measurement of impact on normal function, it would be very interesting 
to see if these pre-treatments can help rectify any of the drug induced functional deficits 
observed in our in vivo model. In addition, experiments involving clinically relevant 
concentrations, patterns of administration, and durations will add to our understanding of 
possible long-term sequelae that cocaine and MDMA may cause, as it is likely that these 
drugs will prove to be increasingly detrimental to the heart in chronic abusers. 
In conclusion, the current findings support our initial hypothesis that cocaine and 
MDMA can significantly disrupt cellular homeostasis and normal heart function. At 
certain concentrations and time points, both drugs activate NF-KB, increase ROS 
generation, elevate intracellular Ca2+, modulate the transcription of certain genes, and 
disrupt the normal function of the intact left ventricle. In the case of cocaine, antioxidant 
and calcium blocking pre-treatment may be of some benefit as prophylactic measures to 
help attenuate myocardial toxicity. Since MDMA alters some of same homeostatic 
parameters as cocaine, albeit with less potency, it is possible that a similar pre-treatment 
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regime may be beneficial with this drug as well. It is likely that additional mechanisms 
and commonalities will reveal themselves upon further research as we gain more insight 
into the nature of these important drugs of abuse. 
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APPENDIX B 
MOUSE CARDIOVASCULAR DISEASE BIOMARKERS ARRAY GENES 
Position Gene name 
APOF 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
ANF 
Apoal 
Apoa2 
Apoa4 
Apoa5 
Apob 
Apocl 
Apoc2 
Apoc3 
Apoc4 
Apod 
APOE 
Apoh 
Scya2 
Cmkbr2/MIP-la 
Ckm 
Crlfl 
Crp 
Ctfl 
Ednl 
Edn2 
Edn3 
TF 
Fga 
Fgb 
FGG 
HMOX1 
ICAM-1 
IFNr 
IL-10 
Description 
Mus musculus, Similar to apolipoprotein 
F, clone MGC: 19128 IMAGE:4211838, 
mRNA, complete cds 
ESTs, Highly similar to ANFMOUSE 
Atrial natriuretic factor precursor (ANF) 
(Atrial natriuretic peptide) (ANP) 
(Prepronatriodilatin) [M.musculus] 
Apolipoprotein A-I 
Apolipoprotein A-II 
Apolipoprotein A-IV 
Apolipoprotein A-V 
Apolipoprotein B 
Apolipoprotein C-I 
Apolipoprotein C-II 
Apolipoprotein C-III 
Apolipoprotein C-IV 
Apolipoprotein D 
Apolipoprotein E 
Apolipoprotein H 
Mus musculus Chemokine (C-C motif) 
ligand 2 
Chemokine (C-C) receptor 2 
Creatine kinase, muscle 
Cytokine receptor-like factor 1 
C-reactive protein, petaxin related 
Cardiotrophin 1 
Endothelin 1 
Endothelin 2 
Endothelin 3 
Coagulation factor III 
Fibrinogen, alpha polypeptide 
Fibrinogen, B beta polypeptide 
Mus musculus fibrinogen gamma-chain 
mRNA, partial cds. 
Mus musculus heme oxygenase 
(decycling) 1 
Intercellular adhesion molecule 
Interferon gamma 
Interleukin 10 
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Position 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
Gene name 
IL-18 
IL-lb 
IL1RN 
IL-6 
Gpl30 
LFAlb/Cd49b 
Cd41b 
Cd49c 
VLA-4 
Integrin a5 
Integrin a6 
Integrin a7 
Integrin a8 
Itga9 
Itgae 
LFAla/CDllA 
Cdllb 
Cd51 
Cdllc 
CD29 
Cdl8 
CD61 
Integrin b4 
Integrin b5 
Integrin b6 
Integrin b7 
TNFb 
LT-b 
Mb 
Clg/Mmpl 
Gelatinase A 
Gelatinase B 
Mrpll5 
65 
66 
NFkBl 
iNOS 
Description 
Interleukin 18 
Interleukin 1-beta (IL-1-beta) mRNA 
Interleukin 1 receptor antagonist 
Interleukin 6 
Mus musculus interleukin 6 signal 
transducer (I16st) 
Integrin alpha 2 
Mus musculus integrin alpha 2b 
Mus musculus integrin alpha 3 
Integrin alpha 4 
Integrin alpha 5 (fibronectin receptor 
alpha) 
Mus musculus integrin alpha 6 
Mus musculus integrin alpha 7 
Integrin alpha 8 
Integrin alpha 9 
Integrin, alpha E, epithelial-associated 
Integrin alpha L 
Mus musculus integrin alpha M 
Mus musculus integrin alpha V 
Mus musculus integrin alpha X 
Integrin beta 1 (fibronectin receptor beta) 
Mus musculus integrin beta 2 
Mus musculus integrin beta 3 
Mouse integrin beta 4 subunit 
Mus musculus integrin beta 5 
Mus musculus integrin beta 6 
Mus musculus integrin beta 7 
Mouse tumor necrosis factor-beta mRNA 
(Lymphotoxin A) 
Mus musculus lymphotoxin B 
Myoglobin 
Mus musculus matrix 
metalloproteinase 13 
Mus musculus matrix metalloproteinase 2 
Mus musculus matrix metalloproteinase 9 
Mitochondrial ribosomal protein LI5 
Nuclear factor of kappa light chain gene 
enhancer in B-cells 1, pi05 
Nitric oxide synthase 2, inducible, 
macrophage 
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Position 
67 
68 
69 
70 
71 
72 
73 
Gene name 
BNP 
LOX-1 
Pappa 
PEC AMI 
Pla2g7 
tPA 
PLAU 
74 PLAUR 
75 
76 
77 
78 
79 
80 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
Pparg 
Saal 
E-selectin 
Selel 
L-selectin 
P-selectin 
Psgll 
PAI-1 
Thbd 
Timp 
TNFa 
TNFR2 
TNFR1 
Cd40 
Fas 
CD40L 
FasL 
Description 
Natriuretic peptide precursor type B 
Oxidized low density lipoprotein 
(lectin-like) receptor 1 
Pregnancy-associated plasma protein A 
Mus musculus platelet/endothelial cell 
adhesion molecule 
Phospholipase A2, group VII (platelet-
activating factor acetylhydrolase, plasma) 
Mus musculus plasminogen activator, 
tissue 
Plasminogen activator, urokinase 
M.musculus muPAR2 mRNA (Urokinase 
plasminogen activator receptor) 
Peroxisome proliferator activated receptor 
gamma 
Serum amyloid A 1 
Selectin, endothelial cell 
M.musculus mRNA for E-selectin 
ligand-1 
Selectin, lymphocyte 
Selectin, platelet 
Selectin, platelet (p-selectin) ligand 
Mouse plasminogen activator inhibitor, 
Serine proteinase inhibitor 
Thrombomodulin 
Tissue inhibitor of metalloproteinase 1 
Mus musculus tumor necrosis factor 
Tumor necrosis factor receptor 
superfamily, member la 
Tumor necrosis factor receptor 
superfamily, member lb 
Tumor necrosis factor receptor 
superfamily, member 5 
Tumor necrosis factor receptor 
superfamily, member 6 
Tumor necrosis factor (ligand) 
superfamily, member 5 
Tumor necrosis factor (ligand) 
superfamily, member 6; Fas ligand 
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Position 
92 
93 
94 
95 
96 
97 
98 
99 
100 
101 
102 
Gene name 
Tnnc 
Tnni3 
Tnnt2 
VCAM-1 
Vwf 
pUC18 
pUC18 
pUC18 
0 
0 
0 
103 GAPDH 
Description 
M.musculus slow/cardiac troponin C 
(cTnC) mRNA, complete cds. 
Troponin I, cardiac 
Troponin T2, cardiac 
Vascular cell adhesion molecule 1 
Von Willebrand factor homolog 
PUC18PlasmidDNA 
PUC18PlasmidDNA 
PUC18PlasmidDNA 
Blank 
Blank 
Blank 
Glyceraldehyde-3 -phosphate 
dehydrogenase 
104 
105 
106 
107 
108 
109 
110 
111 
112 
GAPDH 
CyclophlinA 
CyclophlinA 
CyclophlinA 
CyclophlinA 
RPL13A 
RPL13A 
Beta-actin 
Beta-actin 
Glyceraldehyde-3 -phosphate 
dehydrogenase 
Mus musculus peptidylprolyl isomerase A 
Mus musculus peptidylprolyl isomerase A 
Mus musculus peptidylprolyl isomerase A 
Mus musculus peptidylprolyl isomerase A 
Mus musculus ribosomal protein LI3a 
(23 Kda highly basic protein) 
Mus musculus ribosomal protein LI3a 
(23 Kda highly basic protein) 
Cytoplasmic beta-actin 
Cytoplasmic beta-actin 
APPENDIX C 
MOUSE cAMP/Caz+ SIGNALING PATHWAY FINDER ARRAY GENES 
Position 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
(Ca2 
Gene name 
Aanat 
Adrbl 
ADRB2 
Angiotensinogen 
AHR 
Amdl 
ANF 
Arc 
Amphiregulin 
ATF-3 
Bcl-2 
BDNF 
BRCA1 
Clqrf-pending 
Cables 
Calbl 
Calb2 
Calb3 
CALCRL 
Calmodulin 1 
Calr 
Cyclin Al 
CyclinDl 
Cdk5 
pl5INK4b 
Cga 
Chromogranin A 
Cnnl 
CREB 
CREM-1 
'ARRAY) 
Description 
ArylalkylamineN-acetyltransferase 
Adrenergic receptor, beta 1 
Mus musculus highly similar to beta-2 
adrenergic receptor (Adrb2) 
Mus musculus angiotensinogen 
Aryl-hydrocarbon receptor 
S-adenosylmethionine decarboxylase 1 
ESTs, Highly similar to ANF MOUSE 
ATRIAL NATRIURETIC FACTOR 
PREC 
Activity regulated cytoskeletal-associated 
protein 
Mus musculus amphiregulin 
Activating transcription factor 3 
B-cell leukemia/lymphoma 2 
Brain-derived neurotrophic factor 
Breast cancer 1 
Clq related factor 
Cdk5 and Abl enzyme substrate 
Calbindin-28K 
Calbindin 2 
Calbindin-D9K 
Calcitonin receptor-like 
Calmodulin 1 
Calreticulin 
Mus musculus cyclin Al (Ccnal) 
Cyclin Dl(Ccndl) 
Cyclin-dependent kinase 5 
Cyclin-dependent kinase inhibitor 
pl5INK4b (inhibits CDK4) 
Glycoprotein hormones, alpha subunit 
Mus musculus chromogranin A 
(parathyroid secretory protein 1) 
(precursor for vasostatin) 
Calponin 1 
M.musculus mRNA for transcription 
factor/DNA binding protein 
cAMP responsive element modulator 
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Position 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
Gene name 
Crh 
Cyr61 
Dbh 
GADD153 
Egr-1 
Krox-20 
Eno2 
FGF6 
c-fos 
GOS3 
Follistatin 
Gcg 
Gem 
HK2 
Hspa4 
Grp78 
IL-2 
IL-6 
INHBA 
Jun-B 
51 Jundl 
52 
53 
54 
55 
56 
57 
58 
59 
KCNA5 
Ldhl 
Maf 
MIF 
NCAM 
Nfl 
iNOS 
Neuropeptide Y 
Description 
Corticotropin releasing hormone 
Cysteine rich protein 61 
Dopamine beta hydroxylase 
Mus musculus DNA-damage inducible 
transcript 3 (Ddit3) 
Mouse Egr-1 (Early growth response 1) 
Early growth response 2 
Enolase 2, gamma neuronal 
Fibroblast growth factor 6 
Mouse c-fos oncogene (FBJ osteosarcoma 
oncogene) 
FBJ osteosarcoma oncogene B 
Follistatin 
Glucagon 
GTP binding protein (gene overexpressed 
in skeletal muscle) 
Mus musculus hexokinase 2 mRNA 
heat shock 70 kDa protein 4 
Grp78 (78 KD glucose regulated protein) 
Mouse interleukin-2 
Interleukin 6 
Inhibin beta-A 
Mus musculus Jun-B oncogene 
Mus musculus Jun proto-oncogene related 
gene dl 
Potassium voltage gated channel, shaker 
related subfamily, member 5 
Lactate dehydrogenase 1, A chain 
Highly similar to MAF2 MOUSE 
TRANSCRIPTION FACTOR MAF2 
[M. musculus] 
Mus musculus migration inhibitory factor 
(1 OK protein) 
Mouse mRNA for neural cell adhesion 
molecule 
neurofibromatosis 1 
Inducible nitric oxide synthase 2 
Mus musculus preproneuropeptide Y 
(0710005 A05Rik) 
APPENDIX C CONTINUED 
Position 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
71 
72 
Gene name 
Nr4a2 
Ode 
Pck2-Rik 
PCNA 
Pcx 
Enkephalin 
Perl 
Pitl 
tPA 
Plf 
Pin 
Noxa 
Pou2afl 
Description 
Nuclear receptor subfamily 4, group A, 
member 2 
Ornithine decarboxylase, structural 
RIKEN cDNA 9130022B02 gene 
Proliferating cell nuclear antigen 
Pyruvate decarboxylase 
Mouse Preproenkephalin 1 
period homolog 1 (Drosophila) 
Pituitary specific transcription factor 1 
Mus musculus plasminogen activator, 
tissue (Plat), 
Mus musculus proliferin 
Phospholamban 
Noxa protein (Phorbol-12-myristate-13-
acetate-induced protein 1) 
POU domain, class 2, associating factor 1 
73 Ppp2ca 
74 
75 
76 
77 
78 
79 
80 
81 
82 
83 
84 
85 
Prkarla 
prolactin 
Cox-2 
DUS1 
Rb 
Calgranulin A 
Calgranulin B 
Scg2 
Sgk 
s.Slcl8al 
Smst 
SSTR2 
86 SOD2 
Protein phosphatase 2a, catalytic subunit, 
alpha isoform 
Protein kinase, cAMP dependent 
regulatory, type I, alpha 
Mouse mRNA for prolactin 
Mus musculus prostaglandin-
endoperoxide synthase 2 (Ptgs2) 
Mus musculus protein tyrosine 
phosphatase, non-receptor type 16 
Retinoblastoma protein 
SI00 calcium binding protein A8 
(calgranulin A) 
SI00 calcium binding protein A9 
(calgranulin B) 
Secretogranin II 
Serum/glucocorticoid regulated kinase 
Similar to solute carrier family 18 
(vesicular monoamine), member 1, clone 
MGC:28683 IMAGE:4239930, 
Somatostatin 
Somatostatin receptor 2 
Mus musculus superoxide dismutase 2, 
mitochondrial (Sod2), 
APPENDIX C CONTINUED 
Position 
87 
103 
Gene name 
SRF 
88 
89 
90 
91 
92 
93 
94 
95 
96 
97 
98 
99 
100 
101 
102 
APRF 
substance P 
receptor 
Tcra 
TGFb3 
Th 
THBS1 
TNFa 
Vcl 
Vip 
pUC18 
pUC18 
pUC18 
0 
0 
0 
GAPDH 
104 
105 
106 
107 
108 
109 
110 
111 
112 
GAPDH 
cyclophlinA 
cyclophlinA 
cyclophlinA 
cyclophlinA 
RPL13A 
RPL13A 
beta-actin 
beta-actin 
Description 
Serum response factor (c-fos serum 
response element-binding transcription 
factor) 
signal transducer and activator of 
transcription 3 
Mus musculus tachykinin receptor 1 
T-cell receptor alpha chain 
Transforming growth factor, beta 3 
Tyrosine hydroxylase 
Mouse thrombospondin 1 mRNA 
Mus musculus tumor necrosis factor 
Vinculin 
Vasoactive intestinal polypeptide 
PUC18PlasmidDNA 
PUC18PlasmidDNA 
PUC18PlasmidDNA 
Blank 
Blank 
Blank 
Glyceraldehyde-3 -phosphate 
dehydrogenase 
Glyceraldehyde-3 -phosphate 
dehydrogenase 
Mus musculus peptidylprolyl isomerase A 
Mus musculus peptidylprolyl isomerase A 
Mus musculus peptidylprolyl isomerase A 
Mus musculus peptidylprolyl isomerase A 
Mus musculus ribosomal protein LI3a 
(Rpll3a)(23 Kda highly basic protein) 
Mus musculus ribosomal protein LI3a 
(Rpll3a)(23 Kda highly basic protein) 
Cytoplasmic beta-actin 
Cytoplasmic beta-actin 
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Position 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
Gene name 
annexin A5 
ATM 
bax 
bcl-x 
bcl-w 
caspase-1 
caspase-8 
cyclin C 
cyclin Dl 
cyclin G 
p21Wafl (p21cii 
cryab (a-Crystall 
B) 
GM-CSF 
Cyplal 
Cypla2 
Cyplbl 
Cyp2a5 
Cyp2bl0 
Cyp2b9 
Cyp2c29 
Cyp3al 1 
Cyp4al0 
Cyp4al4 
Cyp7al 
Cyp7bl 
GADD153 
Hsj2 
E2F-1 
egr-1 
Description 
Mus musculus annexin A5 (Anxa5), 
Ataxia telangiectasia mutated homolog 
(human) 
Bcl2-associated X protein 
Bcl2-like 
Bcl2-like 2 
Interleukin-1 beta convertase (IL-lbc) 
Caspase 8 
Cyclin C 
Cyclin Dl 
Cyclin G 
Cyclin-dependent kinase inhibitor p21 Wafl 
Alpha crystallin B 
Colony stimulating factor, granulocyte 
macrophage 
Cytochrome P450, lal , aromatic compound 
inducible 
Cytochrome P450, la2, aromatic compound 
inducible 
Cytochrome P450, lbl , benz[a]anthracene 
inducible 
cytochrome P450, 2a5 
musculus cytochrome P450, 2b 10, 
phenobarbitol inducible, type b (Cyp2bl0) 
Cytochrome P450, 2b9, phenobarbitol 
inducible, type a 
cytochrome P450, 2c29 
Cytochrome P450, steroid inducible 3a 11 
cytochrome P450, 4a 10 
cytochrome P450, 4a 14 
cytochrome P450, 7a 1 
Cytochrome P450, 7b 1 
Mus musculus DNA-damage inducible 
transcript 3 
DnaJ (Hsp40) homolog, subfamily A, 
member 1 
E2F transcription factor 1 
Early growth response 1 
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Position 
30 
31 
Gene name 
Ephx2 
ERCC1 
Description 
Epoxide hydrolase 2, cytoplasmic 
Excision repair cross-complementing 
rodent repair deficiency, complementation 
group 1 
32 
33 
34 
45 
46 
XPD 
XPF 
XPG 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
FMOl 
FM04 
FM05 
Gadd45 
GADD45 b 
GPX1 
GPX2 
GSR 
MGST1 
Gstm3 
HMOX1 
HMOX2 
47 
48 
49 
50 
51 
52 
53 
hsfl (tcf5) 
Hspl05 
hsp25 (hspbl) 
Hsp60 
hsp68 
Hspall 
Hspa4 
Excision repair cross-complementing 
rodent repair deficiency, complementation 
group 2 
Excision repair cross-complementing 
rodent repair deficiency, complementation 
group 4 
Excision repair cross-complementing 
rodent repair deficiency,complementation 
group 5 
Mus musculus flavin containing 
monooxygenase 1 (Fmol), 
Mus musculus flavin-containing 
monooxygenase 4 
Mus musculus flavin containing 
monooxygenase 5 (Fmo5), 
DNA-damage inducible transcript 1 
Growth arrest and DNA-damage inducible 
45beta 
Mus musculus glutathione peroxidase 1 
Mus musculus glutathione peroxidase 2 
Mus musculus glutathione reductase 1 
Glutathione S-transferase, mu 1 
Glutathione S-transferase, mu 3 
Mus musculus heme oxygenase 
(decycling) 1 
Mus musculus heme oxygenase 
(decycling) 2 
M.musculus mRNA for heat shock 
transcription factor 1 
Heat shock protein, 105 kDa 
Mus musculus heat shock protein HSP27 
(Heat shock protein, 25 kDa) 
Heat shock protein, 60 kDa 
Heat shock protein, 70 kDa 1 
Heat shock 70kD protein 1 -like 
Heat shock 70 kDa protein 4 
APPENDIX D CONTINUED 
Position 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
Gene name 
grp78 
hsc73 
PBP74 
chaperonin 10 
Igfbp6 
IL-18 
IL-la 
IL-lb 
IL-6 
TNFb 
64 Mdm2 
65 
66 
67 
68 
69 
70 
71 
72 
73 
74 
75 
76 
77 
78 
79 
80 
81 
MIF 
MT1A 
Mt2 
NFkBl 
ikBa (Mad3) 
iNOS (NOS2) 
PCNA 
NADPH P450 
Cox-2 
RAD23A 
RAD50 
chk2 
Scya21a 
Scya21b 
MIP-2 
(SCYA21) 
MIP-la(SCYA3L 
MIP-lb(Scya4) 
Description 
Grp78 (78 KD glucose regulated protein) 
Heat shock 70kD protein 8 
Heat shock protein, 74 kDa, A 
Heat shock 10 kDa protein 1 
(chaperonin 10) 
Mus musculus insulin-like growth factor 
binding protein 6 (Igfbp6), 
Mus musculus interleukin 18 (II18) 
Mouse interleukin 1, alpha 
Mouse interleukin 1-beta (IL-1-beta) 
mRNA 
Interleukin 6 
Mouse tumor necrosis factor-beta mRNA 
Transformed mouse 3T3 cell double 
minute 2 
Mus musculus migration inhibitory factor 
(1 OK protein) 
Metallothionein-I activator 
Metallothionein 2 
Nuclear factor of kappa light chain gene 
enhancer in B-cells 1, pi05 
Mus musculus I-kappa B alpha chain 
Inducible nitric oxide synthase 
Proliferating cell nuclear antigen 
NADPH-cytochrome P450 
oxidoreductase 
Mus musculus prostaglandin-
endoperoxide synthase 2 (Ptgs2) 
Mus musculus RAD23a homolog (S. 
cerevisiae) 
Mus musculus DNA repair protein 
RAD50 mRNA 
Mus musculus protein kinase Chk2 
(Rad5 3-pending) 
Small inducible cytokine A21a (serine) 
Small inducible cytokine A21b (leucine) 
Mus musculus small inducible cytokine 
A21c (serine) (Scya21c) 
Macrophage inflammatory protein (MIP) 
M.musculus MIP-lb gene for macrophage 
inflammatory protein lb 
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Position 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
Gene name 
IP-lO(ScyblO) 
PAI-1 
SOD1 
SOD2 
TNFR2 
Trail 
FasL 
TRADD 
p53 
UGTBr/p 
UNG 
93 
103 
XRCC1 
94 
95 
96 
97 
98 
99 
100 
101 
102 
XRCC2 
XRCC4 
Ku80 
pUC18 
pUC18 
pUC18 
0 
0 
0 
GAPDH 
104 
105 
106 
107 
108 
GAPDH 
cyclophlinA 
cyclophlinA 
cyclophlinA 
cyclophlinA 
109 RPL13A 
Description 
Interferon-gamma induced protein CRG-2 
precursor (homologous to human IfilO) 
Mouse plasminogen activator inhibitor 
Cu/Zn superoxide dismutase 
Mus musculus superoxide dismutase 2, 
mitochondrial 
Murine tumor necrosis factor II receptor 
TNF-related apoptosis inducing ligand 
Fas ligand 
ESTs, Weakly similar to tumor necrosis 
factor receptor type 1 associated protein 
Transformation related protein 53, Tumor 
antigene 
Mus musculus (A-l) bilirubin/phenol 
UDP-glucuronosyltransferase (UGTBr/p) 
Human cDNA for uracil-DNA 
glycosylase 
Mus musculus X-ray repair 
complementing defective repair in 
Chinese hamster cells 1 
Mus musculus X-ray repair 
complementing defective repair in 
Chinese hamster cells 2 
Mus musculus XRCC4 
Mus musculus Ku autoantigen 
PUC18PlasmidDNA 
PUC18PlasmidDNA 
PUC18PlasmidDNA 
Blank 
Blank 
Blank 
Glyceraldehyde-3 -phosphate 
dehydrogenase 
Glyceraldehyde-3 -phosphate 
dehydrogenase 
Mus musculus peptidylprolyl isomerase A 
Mus musculus peptidylprolyl isomerase A 
Mus musculus peptidylprolyl isomerase A 
Mus musculus peptidylprolyl isomerase A 
Mus musculus ribosomal protein LI3a 
(Rpll3a)(23 Kda highly basic protein) 
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Position Gene name Description 
Mus musculus ribosomal protein LI3a 
110 RPL13A (Rpl 13a)(23 Kda highly basic protein) 
111 beta-actin Cytoplasmic beta-actin 
112 beta-actin Cytoplasmic beta-actin 
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